












for the award of the degree
 
‚Doctor rerum naturalium‘
at the Georg-August-Universität Göttingen
within the doctoral programme Molecular Medicine




Kassel, 11th of May 2020
4 5
Members of the Thesis Advisory Committee:
Referee:
PD Dr. Laura Cecilia Zelarayán Institute of Pharmacology and Toxicology





Prof. Dr. Elisabeth Zeisberg Clinic for Cardiology and Pneumology




Prof. Dr. Steven Johnsen Clinic for General, Visceral and Pediatric Surgery




Additional members of the Examination Board
Prof. Dr. Argyris Papantonis Institute of Pathology









Prof. Dr. Hubertus Jarry Animal Welfare Officer






22......Figure 1. TBX5 acts as a transcriptional activator or repressor depending on interacting factors
25......Figure 2. CX43 and TBX5 expression in the myocardium and isolated cardiomyocytes
26......Figure 3. Regulation of TBX5-expression and activity.
27......Figure 4. Reduced expression of TBX5 in human cardiomyopathy samples
29......Figure 5. Scheme summarising the project Aims
43......Figure 6. Generation of a cardiac specific TBX5 KO mouse model.
50......Figure 7. Cloning of putative enhancers
55......Figure 8.  Schematic of Chromatin Immunoprecipitation
58......Figure 9. A ventricular specific KO of Tbx5 results in a decreased survival rate
59......Figure 10. Tbx5 KO leads to reduced heart growth
60......Figure 11. TBX5 KO leads to diastolic dysfunction
61......Figure 12. Timecourse analysis of ECG parameters shows gradual prolongation of PR- and QRS-intervals 
in vTbx5KO mice
62......Figure 13. vTbx5KO mice develop ventricular and supraventricular arrhythmias
63......Figure 14. vTbx5KO hearts show slower signal propagation
65......Figure 15. Establishment of the TBX5-ChIP-Seq
66......Figure 16. TBX5 co-occupies active enhancers with NKX2.5 and GATA4
68......Figure 17. Comparison of adult and embryonic TBX5 ChIP-Seq
69......Figure 18. Integrative chromatin occupancy and transcriptome analysis identified clusters of novel puta-
tive TBX5 downstream targets in the adult ventricle
70......Figure 19.  Validation of identified genes regulated in vTbx5KO
71......Figure 20.  Gja1 and Kcnj5 are transcriptionally regulated by TBX5
72......Figure 21. Armh4 is downregulated on mRNA and protein levels in vTbx5KO hearts
73......Figure 22. ARMH4 is localized mainly at the intercalated discs and z-discs of adult mouse cardiomyo-
cytes.
74......Figure 23. De-novo motifs found enriched in the TBX5-ChIP-Seq
76......Figure 24. Chromatin occupancy by MEIS1 and TBX5
77......Figure 25. AAV6-in vitro validation in neonatal rat cardiomyocytes
78......Figure 26. AAV9-mediated TBX5 delivery leads to cardiac specific re-expression of TBX5
79......Figure 27. In vivo re-expression of TBX5 restores TBX5 mediated transcription
80......Figure 28. In vivo TBX5 re-expression has no significant effect on functional parameters measured by 
echocardiography
81......Figure 29. In vivo TBX5 re-expression rescues arrhythmic phenotype of vTbx5KO mice




23......Table 2. Target genes
27......Table 3. DCM and ICM Patient characteristics
30......Table 4. Devices used 
30......Table 5. Software used
31......Table 6. Consumables
32......Table 7. Chemicals
33......Table 8. Enzymatic reactions
34......Table 9. Antibodies used
34......Table 10. Commercial plasmids
35......Table 11. Primers used for qRT-PCR, annealing temperature 60°C for all listed primer pairs
36......Table 12. Primers used for cloning
36......Table 13. Primers used for ChIP-qPCRs
37......Table 14. Buffers for SDS-PAGE and Western Blotting
38......Table 15. Buffers for Immunostaining
39......Table 16. Buffer for Agarose Gelelectrophoresis
39......Table 17. Kits
39......Table 18. Bacteria
39......Table 19. Cell lines
40......Table 20. Cell culture reagents
40......Table 21. Buffers for neonatal rat cardiomyocyte isolation
40......Table 22. Buffers for murine adult cardiomyocyte isolation
41......Table 23. Buffers for Chromatin Immunoprecipitation
44......Table 24. Echocardiographic parameters
46......Table 25. Reagents used for reverse transcription
47......Table 26. Reagents used for qPCR (per well)
47......Table 27. Program used for qPCR
49......Table 28. Paraffin embedding
49......Table 29. Deparaffinisation
51......Table 30. Reagents used for Phusion PCR
51......Table 31. Program for Phusion PCR
51......Table 32. Reagents used for A-Tailing
52......Table 33. Reagents used for Ligation
53......Table 34. Reagents used for Transfection for Luciferase assays (24-well plate)
53......Table 35. Reagents used for Transfection for Western Blot (6-well plate)
75......Table 36. Motif analysis in TBX5-ChIP-Seq peaks
90......Table 37. Comparison of different TBX5-ChIP-Seq datasets
113....Table 38. Downregulated genes with a log2-fold-change (L2FC) <-0.8 and p <0.05




This project has been financially supported by a DZHK Shared 
Expertise and a Start-Up Grant of the University Medical centre 
of Göttingen. I was personally supported by a Promotionsstipen-
dium of the Studienstiftung des deutschen Volkes.
I wish to express my deepest gratitude to Dr. Maria Patapia Za-
feiriou, who gave me the opportunity to conduct this project in 
the first place. She took me in in my first practical in my master 
studies, when I had no idea about research in the university and 
about standards of scientific writing. I learned a lot of that from 
scratch under her supervision. She gave me freedom to bring in 
my own ideas and to attend conferences and workshops which 
helped me to personally and scientifically develop. 
A special thank you goes to PD Dr. Laura Zelarayán for giving 
feedback and being available for questions. I thank my thesis ad-
visory committee, Prof. Dr. Elisabeth Zeisberg and Prof. Dr. Ste-
ven Johnson who were encouraging and gave helpful scientific 
advice. Also I want to acknowledge Prof. Dr. Argyris Papantonis, 
Prof. Dr. Rüdiger Behr and Prof. Dr. Hubertus Jarry for volunteer-
ing to take part in my examination.
We collaborated with Partners from Göttingen – NGS Integrative 
Genomics Core Unit conducted RNA- and ChIP-Sequencing and 
analysed the RNA-Seq. Prof. Dr. Steven Johnson and his group 
helped us to establish ChIP-Seq. Namely, Dr. Sankari Nagarajan 
gave input for the sonication part of ChIP and Feda Hamdan 
shared some insights on ChIP-analysis with me. Dr. Rainer Bohrer 
from the GWDG very kindly introduced me to the High-Perfor-
mance Computing Cluster, that finally allowed us to conduct the 
HOMER motif analysis.
External collaboration partners also helped this project. Prof. Dr. 
Larissa Fabritz and her team Fahima Syeda and Nashita Kabir 
conducted the ex-vivo pacing experiments and gave fruitful in-
put in scientific discussions. Prof. Dr. Oliver Müller and his team 
supported us with the plasmids for cloning the AAV-vectors and 
produced and provided the final viral particles. 
Also, I thank Paul Charlton, who gave me a hard time during our 
short encounter for presentation trainings – but that did help, 
and it has brought me forward a lot.
The Institute of Pharmacology and Toxicology was a nice multi-
cultural environment to work in. Several colleagues participated 
directly in this project: The SFB 1002 Service Project S01 con-
ducted operations and echocardiographic investigations and as-
sisted in general with mouse work. Lavanya was very important 
for everything concerning ChIP and a cheerful person besides. 
She conducted some experiments and analyses listed in this the-
sis as well.
Several research assistants and students worked in this project: 
Alica, Cord, Denise, Vanessa as well as Alfia, Amara, Yelena and 
Yi-Ching. Simran provided us with NRCMs. 
I learned a lot from Claudia, who gave a lot of helpful advice and 
taught me how to handle mice. Ines also took a share in that. 
Krasimira showed me how to work with human stem cells and 
how to differentiate them to cardiomyocytes.
I appreciated working together with team members Eric, Moni, 
Cheila of AG Zelarayán. I enjoyed the time with several differ-
ent office colleagues during the time, Elena, Elif, Eriona, Farah, 
Funsho, Mina, PL, Satish, Shumon, Tobi. Thank you, Irina and 
Susanne, for lunch and tea sessions improving the morale. 
I thank my mother for always believing in me, letting me make 
my own decisions and support me when needed. 
Life has changed, since Ilverin has entered the world. He made 
everything more colourful, more intense and he made time fly. 
Therefore, I would like to thank Pascal for clearing time slots for 
me to write this Thesis, for all his moral support and for taking 
care of the visuals during the journey and of this final ‘book’. 





Cardiovascular disease is a common cause of death. About 60 % of cardiovascular mor-
tality is attributable to sudden cardiac death, mostly caused by arrhythmia. The origin of 
arrhythmia can be an underlying chronic cardiac disease, but genetic factors are involved 
as well, especially in younger patients. A genetic factor associated with arrhythmia is 
the transcription factor T-box 5 (TBX5). Most studies investigated TBX5 in the context of 
developmental processes or with respect to conduction properties of the heart. Interest-
ingly, TBX5 expression is dysregulated not only due to genetic factors: Ventricular samples 
from patients or animal models with cardiomyopathy show lower TBX5 expression than 
controls. Because of this aberrant expression pattern in the working myocardium, we hy-
pothesized, that TBX5 plays an important role for tissue homoeostasis of the ventricular 
working myocardium.
 Methods & Results
To investigate the consequences of TBX5 loss in the working myocardium, we generated 
an inducible primarily ventricular TBX5 KO model (vTbx5KO). This led to reduced heart 
growth and diastolic dysfunction in the vTbx5KO. Moreover, the mice presented with im-
peded conduction marked by PR- and QRS-prolongation and arrhythmias characterized 
by atrioventricular block and ventricular tachycardia. The survival of the vTbx5KO mice 
was reduced to 40%, probably attributable to sudden cardiac death.
For the determination of the underlying molecular mechanism, we performed integrative 
chromatin occupancy and transcriptome analysis. This analysis revealed 47 targets of 
TBX5 in the adult ventricle. More profound analysis on a subset of genes identified three 
clusters of novel targets implicated in cardiac electrophysiology (Gja1, Kcnj5, Kcng2, Cac-
na1g, Chrm2), cardioprotection (Fhl2, Gpr22, Fgf16) and contraction (Fstl4, Cmya5, Emi-
lin2, Pdlim4).
Furthermore, we aimed to evaluate the therapeutic potential of restoration of TBX5 ex-
pression to revert arrhythmia and prevent sudden cardiac death. For this purpose, ade-
no-associated virus (AAV) encoding TBX5 were injected in vTbx5KO mice, that already 
suffered from arrhythmia. Indeed, the AAV led to a restoration of TBX5 and its target 
genes and more importantly to a normalisation of conduction and reduced arrhythmic 
propensity.
Conclusions
This study showed that beyond its role in the developing and adult conduction system, 
TBX5 is required for tissue homoeostasis and electrical signal propagation of the working 
myocardium. Its restoration after TBX5 loss can normalise target gene expression and 
cardiac electrophysiology.
Hintergrund
Herz-Kreislauferkrankungen zählen zu den häufigsten Todesursachen. Mehr als 60% die-
ser Todesfälle sind auf den durch Arrhythmien ausgelösten plötzlichen Herztod zurückzu-
führen. Arrhythmien können sowohl durch chronische Herzerkrankungen als auch durch 
genetische Faktoren - besonders bei jüngeren Patienten - hervorgerufen werden. Einer 
dieser Faktoren ist der Transkriptionsfaktor T-box 5 (TBX5), der mit Arrhythmien assoziiert 
ist. Bisher hat sich die Forschung hauptsächlich auf die Rolle von TBX5 in der Entwick-
lungsbiologie und Erregungsleitung im Herzen konzentriert. Jedoch ist die Expression von 
TBX5 nicht nur im Kontext von genetischen Veränderungen, sondern auch in den kardi-
alen Ventrikeln von Patienten oder Tiermodellen mit Herzinsuffizienz reduziert. Wegen 
dieser verminderten Expression im Arbeitsmyokard, stellten wir die Hypothese auf, dass 
TBX5 ebenfalls eine wichtige Rolle für die Homöostase des ventrikulären Arbeitsmyokards 
spielt.
Methoden & Ergebnisse
Um die Folgen des TBX5-Verlusts im Arbeitsmyokard zu untersuchen, generierten wir 
ein induzierbares TBX5-KO-Modell mit prädominanter ventrikulärer Spezifität (vTbx5KO). 
Dies hatte ein reduziertes Herzwachstum und eine diastolische Dysfunktion für die vTbx-
5KO zur Folge. Zudem zeigten die Mäuse eine verlangsamte Erregungsleistung, Arrhyth-
mien wie atrioventrikulären Block und Kammertachykardien, die die Überlebenswahr-
scheinlichkeit der Mäuse auf 40% reduzierten, vermutlich durch das erhöhte Risiko eines 
plötzlichen Herztodes.
Um den zugrundeliegenden molekularen Mechanismus zu untersuchen, führten wir eine 
integrierte Analyse der Chromatinbindung von TBX5 zusammen mit einer Transkriptoma-
nalyse der fehlregulierten Transkripte durch. Diese Analyse zeigte 47 neue Zielgene von 
TBX5 in den adulten Ventrikeln. Die validierten Zielgene lassen sich drei Gruppen zuord-
nen: Gene, mit einer Funktion in der kardialen Elektrophysiologie (Gja1, Kcnj5, Kcng2, 
Cacna1g, Chrm2), Kardioprotektion (Fhl2, Gpr22, Fgf16) und Kontraktion (Fstl4, Cmya5, 
Emilin2, Pdlim4).
Zur Evaluierung des therapeutischen Potentials einer Wiederherstellung der TBX5 Expres-
sion im Hinblick auf Arrhythmiereduzierung und Herztodprävention injizierten wir ar-
rhythmische vTbx5KO-Mäuse mit TBX5-codierenden adeno-assozierten Viren. Tatsächlich 
konnte diese Transduktion die Expression von TBX5 und seiner Zielgene wiederherstellen 
und - noch wichtiger - die Erregungsweiterleitung normalisieren und das Arrhythmierisi-
ko reduzieren.
Schlussfolgerungen
Diese Studie zeigt, dass TBX5 nicht nur in der Entwicklung und der Erregungsleitung eine 
essentielle Rolle spielt, sondern auch für die Homöostase des Arbeitsmyokards essentiell 
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AME Analysis of Motif Enrichment
ANF/ANP Atrial natriuretic factor/peptide
AngII Angiotensin II
AP Alkaline Phosphatase
APD action potential duration
Armh4 armadillo-like helical domain containing 4
bp base pairs
BrdU 5-bromo-2’-deoxyuridine
BSA bovine serum albumine
Cacna1g calcium channel, voltage-dependent, T-type, alpha 1G subunit
CASQ2 calsequestrin 2
CBFHH Calcium and bicarbonate free Hanks with HEPES
cDNA copy DNA
CEAS cis-regulatory element annotation system
ChIP chromatin immunoprecipitation
Chrm2 cholinergic receptor, muscarinic 2, cardiac
CM cardiomyocytes
CMV cytomegalovirus
Cmya5 Cardiomyopathy associated 5
CP cardiac progenitor cells
CVD cardiovascular disease
CX43 Connexin 43 /Gja1
Da Dalton
DCM Dilated cardiomyopathy




E. coli Escherichia coli
ECG electrocardiogram
EHM engineered human myocardium
Emilin2 Elastin microfibril interface located protein 2
FBS fetal bovine serum
Fbxo25 F-box protein 25
FD Fast Digestion
Fgf10 fibroblast growth factor 10
Fgf16 fibroblast growth factor 16
Fgf8 fibroblast growth factor 8
Fhl2 Four-and-a-half LIM domains 2
Fstl4 follistatin-like 4
GAPDH glyceraldehyde 3-phosphate dehydrogenase
GATA4 GATA binding protein 4
GIRK4 G-protein coupled inward rectifier potassium channel
Gja1 gap junction a1 /Cx43
Gja5 gap junction protein alpha 5
GO Gene Ontology
Gpr22 G-Protein coupled receptor 22
GREAT Genomic Regions Enrichment of Annotations Tool
H3K27ac Histone 3, acetylated at the 27th lysine residue
HDAC histone deacetylase
HEK human embryonic kidney






IRX3 Iroquois homeobox 3
kb kilo basepairs
Kcng2 potassium voltage-gated channel, subfamiliy G, member 2
Kcnj5 potassium inwardly-rectifying channel, subfamily J, member 5 (encodes GIRK4)
kDa kilodalton
KO Knock-out
KO-CT vTbx5KO mice transduced with AAV9-LUC
KO-RE vTbx5KO mice transduced with AAV9-TBX5
LA left atrium
LB Lysogeny Broth
LMP4 LIM mineralization protein 4 (PDZ and LIM domain protein 7 - Pdlim7)
LQT long QT syndrome
LV left ventricle
MACS Model-based Analysis of ChIP-Seq
18 19
MCS multiple cloning site
MEF 2 myocyte enhancer factor 2
MEIS 1/2/3 Meis homeobox 1/2/3
miR microRNA
mRNA messenger RNA
Myh6 myosin, heavy polypeptide 6, cardiac muscle, alpha
NF non-failing hearts
NKX2.5 NKX2 homeobox  5
Nppa/b natriuretic peptide type A / B
NRCM neonatal rat cardiomyocyte
NuRD Nucleosome Remodeling and Deacetylase
NYHA New York Heart Association
PAGE Polyacrylamide gel electrophoresis
PBS phosphate buffered saline
PCR polymerase chain reaction
Pdlim4 PDZ and LIM domain 4
PFA paraformaldehyde
POL2 RNA Polymerase II
PVDF polyvinylidene difluoride
qPCR quantitative polymerase chain reaction
RA retinoic acid




Sall4 spalt like transcription factor 4
SCD sudden cardiac death
SCF Skp, Cullin, F-box containing complex
Scn5a/Nav1.5 sodium channel, voltage-gated, type V, alpha
SDS sodium dodecyl sulfate
SEM standard error of the mean
SERM selective estrogen receptor modulator
Shh sonic hedgehog
SNP single nucleotide polymorphism
TAC transverse aortic constriction
TBE T-box binding element
TBX5 T-box 5
TGF-β transforming growth factor, beta 1
TnnT Troponin T
TPX poly(4-methyl-1-pentene)









Previous studies have studied the role of TBX5 during development and found it to be es-
sential for heart development. Mice with a homozygous Knock-Out (KO) of TBX5 die during 
embryonic development due to cardiac defects [Bruneau et al., 2001]. A heterozygous global 
KO of TBX5 in mice leads to increased perinatal death, caused by intrauterine heart failure. 
These mice show structural (cardiomegaly, atrial septal defects, dilated atria) and functional 
cardiac abnormalites along with bone defects [Bruneau et al., 2001]. The functional cardiac 
abnormalities include arrhythmias like atrioventricular block [Bruneau et al., 2001] but also 
an impairment of diastolic function [Zhou et al., 2005]. This has been recapitulated in a 
constitutive cardiac specific TBX5 heterozygous KO mouse model (using Nkx2.5-Cre mice), 
in which the mice show diastolic heart failure in the absence of structural defects [Zhu et al., 
2008].
Mice with a tissue-specific KO of TBX5 in the adult conduction system show an arrhythmic 
phenotype including slower AV and ventricular conduction, AV-block and sudden cardiac 
death [Arnolds et al., 2012]. Inducible global KO of TBX5 leads to atrial fibrillation, that can 
be attributed to prolonged APD90, early and delayed afterdepolarization and altered Ca2+ 
handling in atrial myocytes [Nadadur et al., 2016].
Outside of heart TBX5 plays a role for the induction of lung morphogenesis by interacting 
with the Wnt and Shh pathways [Steimle et al., 2018]. In this context, it interacts with differ-
ent targets compared to the cardiovascular system.
5.2.4. Binding to DNA and interactions with other transcription factors
TBX5 has been shown to synergistically activate the Nppa promoter by directly interacting 
with NKX2.5 and GATA4 (Figure 1A) [Pradhan et al., 2016],[Hiroi et al., 2001],[Garg et al., 
2003]. In addition, it interacts with MEF2C and myocardin to activate Myh6 transcription 
[Ghosh et al., 2009], [Wang et al., 2011]. TBX5 also physically interacts with Sall4. This inter-
action either enhances activation by TBX5 - e.g. on Fgf10 and Gja5 - or counteracts it - e.g. 
on the Nppa promoter [Koshiba-Takeuchi et al., 2006].
In contrast to its well established function as a transcriptional activator, it has recently been 
shown, that TBX5 can also repress gene expression by interaction with the Nucleosome Re-
modeling and Deacetylase (NuRD) complex (Figure 1B) [Waldron et al., 2016]. This complex 
is involved in chromatin remodelling and represses target gene transcription of e.g. Mef2b. 
The interaction of TBX5 with the NuRD complex is necessary for correct cardiac septation 
[Boogerd et al., 2016][Waldron et al., 2016].
5. Introduction
5.1. Cardiovascular disease and sudden cardiac death
Cardiovascular diseases (CVD) accounted for 31% of deaths worldwide with 17 million peo-
ple dying from CVD in 2008 [Mendis et al., 2011]. About 60 % of cardiovascular deaths can 
be attributed to out-of-hospital sudden cardiac death (SCD), defined as unexpected death 
and mostly caused by arrhythmia [Adabag et al., 2010]. SCD can be explained by underlying 
cardiac disease seen in autopsy in 79.3% of cases, but cannot be explained in 1 out of 5 
cases by visible abnormalities. Genetic variants can lead to fatal arrhythmias causing SCD, es-
pecially in the young [Eckart et al., 2011]. Genes associated with SCD are mostly ion channel 
encoding genes. A defect in an ion channel is termed channelopathy and can lead to elec-
trical disturbances, like Brugada syndrom or prolonged or shortened QT-syndroms [Cerrone 
et al., 2011] [Schwartz et al., 2018]. But not only these channelopathies, also mutations and 
variants of transcription factors regulating the expression of proteins involved in electrical 
signal propagation are directly associated with SCD, such as NKX2 homeobox  5 (NKX2-5) 
[Ellesøe et al., 2016] [Perera et al., 2014], Meis homeobox 1 (MEIS1) [Bouilloux et al., 2016] 
[Pfeufer et al., 2010] [Smith et al., 2011], iroquois homeobox 3 (IRX3) [Koizumi et al., 2016], 
myocyte enhancer factor 2 (MEF2) [Naya et al., 2002] and T-box 5 (TBX5).
5.2. T-box 5
T-box 5 (TBX5) is a transcription factor with an essential role in heart development [Horb et 
al., 1999] and cardiac conduction [Moskowitz et al., 2004]. It regulates the expression of 
proteins implicated in electrical signal propagation of the heart, such as the sodium channel 
protein Scn5a (sodium voltage-gated channel alpha subunit 5) and the gap junction protein 
Gja5 (gap junction protein alpha 5) [Arnolds et al., 2012]. Disturbances of TBX5 expression 
or activity can lead to congenital heart disease and arrhythmia [Bruneau et al., 2001] [Arn-
olds et al., 2012] [Nadadur et al., 2016].
5.2.1. Holt-Oram Syndrome
A haploinsufficiency of TBX5 results in a syndrome called Holt-Oram or heart-hand syndrome, 
which was first described by [Holt et al., 1960]. It occurs mainly via de novo mutations, in 
about 1 of 100,000 newborns [Elek et al., 1991]. Patients show upper-limb malformations, 
congenital heart defects (mostly atrial or ventricular septal defects) and/or cardiac conduc-
tion disorders [Vanlerberghe et al., 2019].
5.2.2. Genome-wide association studies
In humans, a genome wide association study revealed a strong correlation between the 
single nucleotide polymorphism (SNP) rs3825214 in an intron of TBX5 and atrial fibrillation 
as well as atrioventricular block. Additionally this SNP was associated with prolongation in 
QRS-, PR- and QT-interval [Holm et al., 2010]. 
Two other studies have also found TBX5 to be associated with abnormal PR-intervals in pop-
ulations of European and African American origin [Pfeufer et al., 2010], [Smith et al., 2011].
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Table 2. Target genes
Gene Long name Interacting 
with
TBX5 action References





activation [Bruneau et al., 2001], [Hiroi 
et al., 2001], [Koshiba-Take-
uchi et al., 2006], [Wang et 
al., 2011], [Pradhan et al., 
2016]
Gja1 gap junction protein, 
alpha 1
PITX2 activation [Nadadur et al., 2016]
Gja5 gap junction protein, 
alpha 5
SALL4 activation [Bruneau et al., 2001], [Arn-
olds et al., 2012], [Koshi-
ba-Takeuchi et al., 2006]
Scn5a sodium channel, volt-
age-gated, type V, 
alpha
PITX2 activation [Arnolds et al., 2012], [van 
den Boogaard et al., 2012], 
[Nadadur et al., 2016]
Kcnj5 potassium inward-
ly rectifying channel 
subfamily J member 
5
activation [Nadadur et al., 2016]
Fhl2 Four and a half LIM 
domains 2
activation [Mori et al., 2006]
Myh6 myosin, heavy pol-




activation [Ghosh et al., 2009], [Wang 
et al., 2011]
Atp2a2 ATPase, Ca++ trans-
porting, cardiac mus-
cle, slow twitch 2
PITX2 activation [Zhu et al., 2008], [Nadadur 
et al., 2016]
Ryr2 ryanodine receptor 2, 
cardiac
PITX2 activation [Nadadur et al., 2016]




activation [Nadadur et al., 2016]
Fgf10 fibroblast growth 
factor 10
SALL4 activation [Koshiba-Takeuchi et al., 
























TBX5 acts as a transcriptional activator or repressor depending on interacting factors A. TBX5 
interacts with NKX2.5 and GATA4 to activate transcription by binding to enhancers and promoters on open 
chromatin. B. TBX5 interacts with the NuRD-complex to repress transcription by deacetylation of histones 
thereby remodeling chromatin to an inactive state. Figure adapted from [Boogerd et al., 2016].
5.3. Target genes of TBX5
TBX5 regulates a broad variety of genes, depending on the tissue context and developmental 
stage. Research studies have focused on embryonic development, especially in the heart, and 
on cardiac function with regards to electrophysiology in the adult heart. In these contexts 
several target genes have been identified (Table 2 lists a number of published TBX5 targets).
Known target genes activated by TBX5 include the peptide hormone atrial natriuretic pep-
tide a (Nppa) [Bruneau et al., 2001][Koshiba-Takeuchi et al., 2006] secreted by cardiac atria. 
Others include genes implicated in electrical signalling in the heart like sodium voltage-gated 
channel alpha subunit 5 (Scn5a) [Arnolds et al., 2012][van den Boogaard et al., 2012] or gap 
junction protein alpha 5 (Gja5) [Bruneau et al., 2001][Koshiba-Takeuchi et al., 2006]. A third 
group of genes are involved in development and cell growth, e.g. Wnt2/2b [Steimle et al., 
2018] and Fgf10 [Koshiba-Takeuchi et al., 2006],[Camarata et al., 2006].
In the atria, TBX5 regulates the expression of the transcription factor PITX2 and both regu-
late Gja1, Scn5a, Dsp, Atp2a2 and Ryr2. TBX5 activates expression and PITX2 represses their 
activation [Nadadur et al., 2016]. 
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5.3.1. Functional implications of TBX5 target genes
5.3.1.1. Scn5a
Scn5a has been identified as a TBX5 target gene. An enhancer shortly downstream of 
the gene body is responsible for TBX5 induced regulation [Arnolds et al., 2012][van den 
Boogaard et al., 2012]. Scn5a (sodium channel, voltage-gated, type V, alpha) encodes for a 
subunit of the sodium-selective voltage-dependent channel Nav1.5 and is essential for cardi-
ac contraction [Papadatos et al., 2002]. A complete KO of Scn5a is embryonically lethal and 
a haploinsufficiency leads to a 50% reduction in sodium conductance with the consequence 
of disturbed conduction in atria and ventricles and re-entrant tachycardia [Papadatos et al., 
2002].
5.3.1.2. Gja1
Recently Gja1 has been found to be regulated by TBX5 [Nadadur et al., 2016]. Gja1 encodes 
for Connexin 43 (CX43), the major gap junction protein in the working myocardium [Severs 
et al., 2004]. It is expressed in the atria and ventricles (Figure 2, left and middle panel) and lo-
calized at the cell-cell-junctions (Figure 2, right panel) (own unpublished data). Heart-specific 


















CX43 and TBX5 expression in the myocardium and isolated cardiomyocytes  Besides prominent 
expression in the left atrium (LA) and atrioventricular (AV) node (left panel), TBX5 (red) is expressed to a 
lower extent in the working myocardium of the left ventricle (LV) (middle panel, arrowheads). In isolated 
ventricular myocytes, the expression of CX43 (green) and TBX5 in the same cell is obvious (right panel). 
DAPI (blue) was used to stain nuclei. Scale bars: 20 µm (own unpublished data). 
5.3.1.3. Kcnj5
Kcnj5 (potassium inwardly-rectifying channel, subfamily J, member 5) encodes for G-protein 
coupled inward rectifier potassium channel 4 (GIRK4). It forms a heteromer with GIRK1 in 
the heart [Krapivinsky et al., 1995]. GIRK4 is expressed the intercalated disks of rodent atria 
and ventricles and its expression could be detected in human ventricles [Liang et al., 2014]. 
It contributes to ventricular repolarization [Liang et al., 2014]. Therefore, mutations in the 
KCNJ5-gene in humans lead to Long QT syndrome type 13 (LQT13). Long-QT syndromes can 
be a cause for arrhythmia and sudden cardiac death [Wang et al., 2013].
Wnt2/2b wingless-type MMTV 
integration site fami-
ly, member 2/2B
Shh pathway activation [Steimle et al., 2018]
Gad1 glutamate decarbox-
ylase 1





repression [Waldron et al., 2016]





repression [Waldron et al., 2016]
Nxph4 neurexophilin 4 repression [Waldron et al., 2016]
Sncb synuclein, beta repression [Waldron et al., 2016]
Col20a1 collagen, type XX, al-
pha 1
repression [Waldron et al., 2016]




repression [Waldron et al., 2016]
Klf4 krueppel-like factor 4 
(gut)
repression [Waldron et al., 2016]
Casz1 castor zinc finger 1 repression [Waldron et al., 2016]
Fgf11 fibroblast growth 
factor 11
repression [Waldron et al., 2016]
Plekha2 pleckstin homology 
domain containing 
A2
repression [Waldron et al., 2016]
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5.5. TBX5 in the diseased heart
So far, most studies have focused on the role of TBX5 in the context of its developmental 
function or with respect to genetic alterations of TBX5. But there are a some indications, that 
TBX5 might have a relevance outside of this context.
5.5.1. Rodent models
In a rodent model of cardiac hypertrophy - induced by the chronic infusion of Angiotensin 
II, a peptide hormone inducing blood pressure increase and hypertrophy - TBX5 has been 
found to be downregulated [Baurand Anthony et al., 2007].
Similarly, in a rat heart-on-a-chip model, chronic AngII stimulation resulted in lower TBX5 
levels and its target Scn5a [Horton et al., 2016].
5.5.2. Dysregulated Expression of TBX5 in human cardiomyopathies
Because TBX5 was dysregulated in a murine model of cardiac hypertrophy, the expression 
of TBX5 in human cardiac disease was quantified. Indeed, TBX5 expression was reduced in 
samples from patients receiving a heart transplantation because of dilated (DCM) or ischemic 
(ICM) cardiomyopathies (Figure 4) (own unpublished data). Interestingly, the medical history 
















































Reduced expression of TBX5 in human cardiomyopathy samples TBX5 protein is expressed at 
lower levels in left ventricular samples from patients with dilated (DCM) and ischemic (ICM) cardiomyo-
pathy compared to non-faliling (NF) hearts. Analysis was done by immunoblot and quantified by densi-
tometry. Calsequestrin 2 (CASQ2) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used 
to normalize protein expression. Statistics: One-Way ANOVA, * p<0.05
Table 3. DCM and ICM Patient characteristics
DCM ICM NF
n 4 4 3










Age, range 40-65 47-57
EF, mean (SD) 22.3 % (10) 26.25 % (8)
EF, range 15-40 % 20-40 %
Male, percentage (n) 75% (3) 100% (4)
Female, percentage (n) 25% (1)
History of arrhythmia 100% (4) 100% (4)
5.4. Regulation of TBX5
Protein expression and activity can be regulated on several levels, from transcription through 
translation, post-translational modifications, intracellular localisation to degradation.
5.4.1. Transcriptional regulation
The transcription of the TBX5 gene is activated by retinoic acid (RA) signaling in chicken 
and mice [Liberatore et al., 2000],[De Bono et al., 2018]. While it has been suggested that 
this activation is indirectly mediated by Fgf8 [Zhao et al., 2009], [Cunningham et al., 2013], 
others found a RA-response element in an intron of TBX5 [Nishimoto et al., 2015]. However, 
those studies were carried out on the role of TBX5 in limb development and the regulation 
in the heart might be different. In vitro promoter activation assays showed, that Tbx5 can be 
activated by RA, FHL2 and TBX5 itself [Renger, 2012] (Figure 3A).
5.4.2. Translational regulation & Posttranslational modifications
The translation of TBX5 mRNA into protein was suggested to be regulated by miR-10a and 
miR-10b (Figure 3B), which target the 3’-UTR of TBX5, thereby downregulating TBX5 protein 
levels [Wang F et al., 2014]. When TBX5 protein is acetylated (e.g. by Histone acetyltrans-
ferase p300), its activity increases, whereas deacetylation by histone deacetylase 3 (HDAC3) 
leads to repression of TBX5 activity [Lewandowski et al., 2014] (Figure 3C).
5.4.3. Intracellular localization & Degradation
TBX5 shuttles between the nucleus and the cytoplasm, where it is bound by LMP4 on actin 
filaments (Figure 3D). Thereby, the overexpression of LMP4 can inhibit the activity of TBX5 
[Camarata et al., 2006]. Lastly the degradation of TBX5 by the ubiquitin-proteasome system 
(UPS) seems to be regulated by the F-box protein 25 (Fbxo25) (Figure 3E), which facilitates 



























Regulation of TBX5-expression and activity. A. Tbx5-transcription can be activated by retinoic 
acid (RA), FHL2 and TBX5 itself. B. Tbx5-mRNA can be bound and inhibited by miR-10a and b. C. When TBX5 
is acetylated (e.g. by EP300) its activity increases, deacetylation (by e.g. HDAC3) renders TBX5 to a more 
inactive state. D. LMP4 induced binding of TBX5 to actin-filaments, prohibits TBX5 from entry into the nu-
cleus and thereby hinders its action. E. Degradation of TBX5 in the proteasome is initiated by FBXO25, 
which induces SCF-mediated ubiquitination. See the text (5.4) for references. Factors coloured in green 
are enhancing and factors in purple are inhibiting TBX5 expression/activity. Blue and yellow are structural 
elements.
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Based on the expression of TBX5 in the left ventricle (Figure 2) and its dysreg-
ulated expression in the diseased myocardium (5.5), we formed the following 
hypotheses:
 - TBX5 is important for homoeostasis of the working myocardium.
 - Reduction of TBX5 levels in the ventricles leads to a dysregulation of the 
transcriptional program and a deterioration of cardiac function and rhyth-
micity.
 - Normalization of TBX5 in a loss-of-function model can rescue the tran-
scriptional and phenotypical consequences.
To test these hypotheses we aimed to:
 - Determine the phenotypical consequences of TBX5 loss in the adult heart 
using echo- and electrocardiographic measurements.
 - Uncover the transcriptional consequences of TBX5 loss in the adult heart 
by integrative RNA- and ChIP-Seq analysis
 - Evaluate if TBX5 re-expression in vivo can rescue the phenotype and re-
store TBX5 driven gene transcription
5.6. Adeno-associated virus as a re-expression strategy
Since TBX5 is expressed at a reduced level in the diseased heart, 
it might be a strategy in the treatment of heart failure to restore 
its expression. Therefore, introducing external DNA into organ-
isms is of great interest, as a research tool as well as for clinical 
use. An important tool to deliver DNA to mammals in vivo is the 
use of adeno-associated virus (AAV). To reduce the risk of inte-
gration into the genome, wild-type AAVs have been modified by 
removing the rep gene and are termed recombinant AAV (rAAV) 
[Wang et al., 2019].
Tissue specificity of the AAV-transduction is greatly influenced 
by the serotype used for virus production. For cardiac gene 
transfer, the most widely used serotypes are AAV6 and AAV9 
[Bass-Stringer et al., 2018]. The choice of the promoter driving 
the expression of the transgene affects the specificity, but also 
the expression levels, e.g. the CMV promoter can strongly drive 
expression, but cardiac specific promoters like Troponin T can lead 
to better specificity for the heart [Schwab et al., 2018][Mearini 
et al., 2014].
Already, two recombinant AAVs (rAAVs) have been approved in 
the European Union and the US for gene therapy in humans 
[Wang et al., 2019]. More than 160 trials using rAAVs are regis-
tered [clinicaltrials.gov]. 
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Scheme summarising the project Aims An inducible cardiac-specific TBX5 KO mouse model will 
be used to determine the phenotypical and molecular consequences of TBX5 loss in the adult working 
myocardium. A rescue experiment will be performed to reveal if TBX5 re-expression in vivo can reverse the 
molecular and functional consequences of TBX5 loss.
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GraphPad Prism 8 GraphPad Software
Image Lab Biorad
ND-1000 V3.8.1 Nanodrop Technologies
Ponemah 6.33 DSI
Quantity One 4.6.7 Biorad
SDS 2.4 Applied Biosystems
Serial Cloner 2.6.1 Serial Basics
Soft Max Pro 5.4 Molecular Devices





384-well plates (for qPCR) MicroAmp Optical Reaction Applied Biosystems
384-well adhesive film MicroAmp Optical Adhesive Film Applied Biosystems
96-well (for Bradford) 96-well flat bottom Sarstedt
Cannula / Syringes B.Braun
Cell culture plates 6-well, 12-well Sarstedt
Cell scraper Sarstedt
Chromatography Paper 3 mm Whatman
Glass Cover slips 12 mm Thermo Scientific
PVDF membrane Roti-PVDF®, 0,45 µm Roth
Object slides Thermo Scientific
Osmotic minipumps 1002 Alzet
PVDF membrane Roti-PVDF®, 0,45 µm Roth
Telemetric ECG transmitters ETA-F10 Data Science International
Tissue culture flask 75 cm² Sarstedt
TPX tubes 1.5 ml Bioruptor® Plus TPX diagenode
6. Materials
6.1. Devices
Table 4. Devices used
Device Type Manufacturer
Chemiluminescent Imager ChemiDoc XRS BioRad
CASY cell counter Model TT Roche Innovatis AG
Centrifuges Biofuge Pico Heraeus
3K30 Sigma Laborzentrifugen
5417R Eppendorf
Laminar air flow bench HERAGUARD Thermoscientific
Incubator Certomat HK B. Braun Biotech
Sanyo Sanyo
Gel Imager Gel Doc XR Imaging System Biorad
SDS-PAGE Equipment MiniProtean Biorad
Microscopes Axiovert 200 Carl Zeiss
Leica M80 Leica
LSM 710 Carl Zeiss
Multiplate Reader FlexStation 3 Molecular Devices
PCR cycler T Gradient Biometra
Veriti® 96-well Thermal Cycler Applied Biosystems
qRT-PCR device 7900 HT Fast Real-Time PCR system Applied Biosystems
Spectrophotometer NanoDrop 1000 Peqlab
Sonicator Bioruptor Plus Diagenode
Thermomixer Thermomixer Compact Eppendorf
Tissue Lyser Tissue Lyser II Qiagen
UV Transilluminators TI1 Biometra
6.2. Software
Table 5. Software used
Name Manufacturer
Adobe Illustrator CS6 Adobe
Adobe InDesign CS6 Adobe











Sodium chloride Carl Roth
Tamoxifen Sigma Aldrich
N,N,N',N'-Tetramethylethylendiamin (TEMED) AppliChem
Turbofect Transfection Reagent ThermoScientific






Table 8. Enzymatic reactions
Method Reagents/Enzymes Manufacturer
Dephosphorylation Fast AP Thermosensitive Alka-
line Phosphatase 1 U/µl
Thermoscientific
10x reaction buffer for AP Thermoscientific
Ligation T4 DNA Ligase 5 U/µl Thermoscientific
10 x T4 Ligase buffer Thermoscientific
T4 DNA Ligase 5 U/µl NEB
2x Rapid Ligation buffer NEB
PCR Phusion DNA Polymerase 2 U/
µl
Thermoscientific
5x Phusion HF Buffer Thermoscientific
Dream Taq Thermoscientific
10x Dream Taq buffer with 
MgCl2
Thermoscientific
qPCR GoTaq® qPCR MasterMix 2x Promega
CXR Reference dye Promega
Restriction Fast Digest Enzymes Thermoscientific
10x Fast Digest Green buffer Thermoscientific
Reverse Transcription M-MLV Reverse Transcriptase 
200 U/µl
Promega
M-MLV RT 5x buffer Promega
ChIP Proteinase K (20mg/ml) Pierce
6.4. Chemicals
Table 7. Chemicals
Acetic acid 100% Merck
Acrylamid 30% AppliChem
Agarose Ultra Pure™ AppliChem
Ammonium chloride Carl Roth




Bovine Serum Albumine (BSA) Sigma
Chemoluminescence reagent (FemtoLucent) G Biosciences
Chemoluminescence reagent (LumiGlo) Cell Signaling
Collagen internal production
β-Mercaptoethanol AppliChem
Bradford-Reagent (Roti-Quant) Carl Roth
dNTP PCR Nucleotide Mix (10 mmol/l) Promega
EDTA AppliChem
EGTA AppliChem
embedding solution (Mowiol) Sigma
Ethanol (99,5%) Carl Roth
Ethidium bromide Sigma
Formaldehyde (for ChIP) - 16%, Methanol-free Polysciences







Miglyol (medium-chain triglycerides) Caelo
Milk, non-fatty dried Carl Roth
NP-40 Sigma
Phosphatase Inhibitor (PhosSTOP) Roche
Ponceau S AppliChem
Potassium bicarbonate Carl Roth




Table 11. Primers used for qRT-PCR, annealing temperature 60°C for all listed 
primer pairs
Primer name Primer sequence
Tbx5 rec fwd AGGCAGGGAGGAGAATGTTT


































































anti-TBX5 rabbit Sigma HPA008786 1:1000
anti-flag, monoclonal rabbit Sigma F7425 1:100
anti-flag M2, monoclonal mouse Sigma F1804 1:1000
anti-GAPDH mouse Millipore MAB374 1:50000
anti-Cx43 rabbit Millipore 3512 1:1000 1:100
anti-FHL2 rabbit abcam ab 12327 1:1000
anti-KCNJ5 rabbit Sigma HPA017353 1:250 1:50
anti-α-actinin (sarcomeric) mouse Sigma A7811 1:200
normal rabbit IgG rabbit SantaCruz sc-2027 1:100






anti-rabbit Alexa Fluor 594 goat Invitrogen A11012 1:200
anti-mouse Alexa Fluor 594 goat Invitrogen A11005 1:200
anti-rabbit Alexa Fluor 488 goat Invitrogen A11008 1:200
anti-mouse Alexa Fluor 488 goat Invitrogen A11001 1:200
HRP-conjugated anti-mouse rabbit Dako P0260 1:10000
HRP-conjugated anti-rabbit goat Dako P0448 1:5000
6.7. Commercial plasmids







Table 14. Buffers for SDS-PAGE and Western Blotting







pH adjusted to 7.9; before use Phosphatase and Proteinase Inhibitors 
were added according to manufacturers instructions
Lämmli Buffer 4x Tris-HCl 0,5 mol/l, pH 6,8 2.4 ml
0,5% Bromphenolblau (in Tris-HCl) 0.5 ml
SDS 0.8 g
100% Glycerin 3.0 ml
water ad 9ml
Mercaptoethanol (added to aliquots before use) 1ml
Running buffer (10x) Tris Base 30.3 g/l
Glycin 144 g/l
SDS 10 g/l
dilute to 1x before use
Stacking gel (6 %) Aqua bidest.
Acrylamide 30%




Seperating gel (10%) Aqua bidest.
Acrylamide 30%




Table 12. Primers used for cloning







Table 13. Primers used for ChIP-qPCRs
Primer peak location (mm9) sequences
Scn5a fwd chr9: 119,378,722 - 119,379,682 GGTGTGAATGAGGGAGGCAG
Scn5a rev GGGTGTCTGGGACAGGAGAT
Gja1 fwd chr10: 56,700,503 - 56,701,066 GGTCACATGGTTGCTCGGTA
Gja1 rev CAGCTCGCCTAGTCCACTTC
Fhl2 fwd chr1: 43,304,427 - 43,304,911 CAGTAGCTGTCTGCTGGGAG
Fhl2 rev CATGTGCACACCTCCCTCTT
Fgf16 fwd chrX: 102,968,546 - 102,969,107 GCCAGCTTGAAGTAGCCAGA
Fgf16 rev CTCTCCTAATGAGCGGCCTG
Kcnj5 fwd chr9: 32,121,467 - 32,122,084 TCCTGGCTCCAAAGGATTCAC
Kcnj5 rev ATGGAGAAGAGCCCCTGTCT
Cacna1g fwd chr11: 94,312,360 - 94,313,144 TCCTTGTTCAGACGGTCAGC
Cacna1g rev GCAAGCATGCCTCCCAGATA
Chrm2 fwd chr6: 36,457,945 - 36,458,346 GTGTCAGTTAATTGCAGCGG  
Chrm2 rev TATATTTGAGAAGGAAGGCAGTTTG  




Table 16. Buffer for Agarose Gelelectrophoresis
TAE buffer (50x) Tris Base 242.2 g/l
EDTA 18.6 g/l
Glacial Acetic Acid 57.1 ml/l




Plasmid isolation (Mini) NucleoSpin® Plasmid Macherey Nagel
Plasmid isolation (Maxi) NucleoBond® Xtra Midi Macherey Nagel
RNA isolation NucleoSpin® RNA Macherey Nagel
Gel Extraction and PCR Clean 
up
NucleoSpin® Gel and PCR 
Clean-Up
Macherey Nagel
DNA Clean up after ChIP Buffer NTB for NucleoSpin® Gel 
and PCR Clean-Up
Macherey Nagel
Luciferase assays Dual-Luciferase Reporter Assay Promega




E. coli NEB 10-β competent E. coli NEB
E. coli dam-/dcm- competent E. coli NEB
6.14. Cell culture
Table 19. Cell lines
Cell line Source
HEK293A ATCC, CRL-1573
Transfer buffer (10x) Tris Base 75.6 g/l
Glycine 74.4 g/l
SDS 15 g/l
Transfer buffer (1x) Transfer buffer (10x) 10 ml
Methanol 20 ml
Aqua bidest. 70 ml
TBST Tris/HCl 1 mol/l, pH 7.6 20 ml
NaCl 5 mol/l 33 ml
Tween 20 1 ml
Aqua bidest. ad 1 l
Blocking solution (milk) Non-fat dried milk 50 g/l
TBST ad 1 l
Blocking solution (BSA) BSA 50 g/l
TBST ad 1 l
6.10. Immunostainings
Table 15. Buffers for Immunostaining
Permeabilisation buffer Triton-X-100 3 g/l
BSA 2 g/l
dilute in PBS
Blocking buffer Triton-X-100 1 g/l
BSA 50 g/l
dilute in PBS
Blocking buffer Triton-X-100 1 g/l
BSA 1 g/l
dilute in PBS
Nuclear staining buffer Hoechst 1 µg/ml
dilute in PBS
40 41
Digestion buffer Collagenase B 2 mg / ml
CaCl2 40 µmol/l
diluted in Perfusion buffer
Stop buffer FCS 10%
CaCl2 12.5 µmol/l
diluted in Perfusion buffer
Calcium increasing Step 2 100 µmol/l CaCl2
all in Stop buffer Step 3 400 µmol/l CaCl2
Step 4 900 µmol/l CaCl2
6.16. Chromatin Immunoprecipitation
Table 23. Buffers for Chromatin Immunoprecipitation
FA in PBS Formaldehyde 16% for 2% 1,25 ml
PBS ad 10 ml
directly before use add 1 tablet of Proteinase Inhibitors / 10 ml
Glycin (10x) Glycin 208,95 g/l
Hypotonic buffer HEPES 2,38 g/l
KCl 0,75 g/l
MgCl2 (Hexahydrat) 0,41 g/l
EDTA 0,037 g/l
DTT 0,154 g/l
directly before use add 1 tablet of Proteinase Inhibitors / 10 ml
Sonication Buffer I Tris-HCl 7,88 g/l
EDTA 2,92 g/l
SDS 10,00 g/l
adjust pH to 8, directly before use add 1 tablet of Proteinase Inhibitors 
/ 10 ml





adjust pH to 8, directly before use add 1 tablet of Proteinase Inhibitors 
/ 10 ml
Table 20. Cell culture reagents
Medium Specification Manufacturer
DMEM + Glucose, - Pyruvate Gibco
MEM 2.2 g/l NaHCO3, - Glutamine Gibco
FBS Gibco
Penicillin/Streptomycin 100x Gibco
Transfection reagent Turbofect Thermoscientific
HEK Medium 10% FBS, 1% Penicillin/Streptomycin in 
DMEM
NRCM medium 10% FBS, 1% L-Glutamine, 1% Penicillin/
Streptomycin, 0.1 mmol/l BrdU in MEM
6.15. Cell isolation
Table 21. Buffers for neonatal rat cardiomyocyte isolation
Calcium- and bicarbonate-free 








pH adjusted to 7.4, sterile filtered
Table 22. Buffers for murine adult cardiomyocyte isolation














All animal experiments were approved by the local competent authority (Lower Saxony State 
Office for Consumer Protection and Food Safety - LAVES; AZG15/2029).
7.1.1. Characterization of the TBX5 KO mouse model
To obtain a cardiomyocyte specific TBX5 KO mouse model, two previously published mouse 
strains were crossed (Figure 6A) as described by [Renger, 2012]. The Myh6-MerCreMer 
mouse encodes Cre-recombinase fused to a modified estrogen-receptor under control of 
the Myosin heavy chain, alpha isoform (Myh6) promoter. Thus the MerCreMer is expressed 
exclusively in cardiomyocytes and only activated once the selective estrogen receptor mod-
ulator (SERM) Tamoxifen is administered [Sohal Dawinder S. et al., 2001]. These mice were 
crossed with the TBX5LDN/LDN mouse model, harbouring loxP sites flanking Exon3 of the Tbx5 
gene. The resulting mouse model thereby allows removal of the DNA-binding domain of 
the TBX5 transcription factor [Mori et al., 2006] upon Tamoxifen exposure. We detected 
MerCreMer expression specifically in the nuclei of cardiomyocytes from atrial and ventricular 
tissue (Figure 6B). All crossings were done on a C57BL/6N background.
Figure 6. 
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Generation of a cardiac specific TBX5 KO mouse model. A. A transgenic mouse strain with Ta-
moxifen-inducible Cre recombinase under the control of the Myosin heavy chain, alpha isoform (Myh6) 
was crossed with a mouse model containing loxP sites flanking Exon 3 of the Tbx5 gene to obtain a cardi-
omyocyte specific inducible KO model. B. The MerCreMer fusion protein is exclusively expressed in the 
nuclei of cardiomyocytes.
ChIP incubation buffer NaCl 2,92 g/l
Tris-Cl 7,88 g/l
EDTA 1,46 g/l
adjust pH to 7.5, directly before use add 1 tablet of Proteinase Inhibi-
tors / 10 ml
Wash buffer 1 NaCl 4,38 g/l
Tris-Cl 7,88 g/l
EDTA 2,92 g/l
adjust pH to 7.5
Wash buffer 2 NaCl 7,31 g/l
Tris-Cl 7,88 g/l
EDTA 2,92 g/l
adjust pH to 7.5
Wash buffer 3 NaCl 10,23 g/l
Tris-Cl 7,88 g/l
EDTA 2,92 g/l
adjust pH to 7.5




adjust pH to 7.5
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Volume in systole Vol s µl (5/6) x (Area s x Ls)
Volume in diastole Vol d µl (5/6) x (Area d x Ld)
Ejection fraction EF % SV / Vol d x 100
Stroke volume SV µl Vol d - Vol s
Cardiac output CO ml/min SV / 1000 x HR
Cardiac index CI l /
(min*g)
CO / BW x 1000
heart weight HW mg 1,05 x (5/6) x ((Epi s x (Ls + 
(AWThs+PWThs)/2))) - (Area s x Ls))
heart weight to body weight HW/BW mg/g HW / BW
7.1.5. Organ Harvest
To harvest organs, mice were either anaesthetized with Isofluran and subsequently killed by 
cervical dislocation or received terminal anaesthesia by injection of Ketamin (ca. 160 mg/kg) 
and Xylazin (ca. 16 mg/kg) until loss of reflexes. The mice were opened at the chest and the 
heart was removed and rinsed in PBS to remove blood. Atria were kept separately in liquid 
nitrogen, the central part of the ventricles (cross-section) was fixed for histology in 4 % PFA 
at 4°C over night. Upper and apical parts of the ventricles were meshed and snap-frozen in 
liquid nitrogen before storing them at -80°C for later isolation of RNA or protein.
7.1.6. Ex vivo electrophysiological recordings
The method of ex vivo recordings of arrhythmia induction and measurement of activation 
times has been described previously [Wittköpper et al., 2010]. All experiments have been 
done at the University of Birmingham by Fahima Syeda, Nashita Kabir and Larissa Fabritz.
In brief, hearts were excised under deep terminal anaesthesia. The aorta was cannulated for 
retrograde perfusion with Krebs-Henseleit buffer on a Langendorff apparatus. 
After inserting an octapolar mouse electrophysiologic catheter in the right atrium and ven-
tricle, monophasic action potentials were recorded continuously and simultaneously on the 
right ventricular free wall, septum and on the left ventricular free wall epicardium. To meas-
ure activation times from right atrium to right ventricle, atrial S1 pacing was used. To deter-
mine ventricular activation times, the right ventricular endocardium was paced. 
Ventricular arrhythmia inducibility was determined by programmed ventricular stimulation 
with a single encroaching premature stimulus (S2). Experiments were performed and ana-
lysed when the observer was unaware of the mouse genotype. 
7.1.2. Tamoxifen induction
For the activation of Cre recombinase by Tamoxifen, mice were injected with 30 mg Tamox-
ifen per kg body weight at the age of 8-12 weeks for consecutive 3 days in a row. Tamoxifen 
was dissolved in Ethanol at 75 mg/ml while warming at ~35°C for ~10 minutes. This solution 
was further diluted in Miglyol to a final concentration of 7.5 mg/ml and subsequently used 
for intraperitoneal (i.p.) injections.
7.1.3. Telemetry implantation and recordings
Telemetry devices were implanted before injection of Tamoxifen according to [Vettel Chris-
tiane et al., 2017]. Briefly described, electrocardiograms (ECG) were recorded for 24 hours 
each. They were evaluated with Ponemah P3, Version 6.33 using template based analysis for 
PR-, QRS- and QT-determination. For heart rate variability analysis RR-intervals were exported 
from Ponemah for intervals of 5 mins, which were manually checked and adjusted for correct 
R-placements. These data were imported and evaluated to HRVAS as ibi-files, which allowed 
calculation of standard-deviations [Ramshur, 2010].
7.1.4. Echocardiography
Mouse heart dimension and function was assessed by echocardiography in unconscious mice 
(2% isofluran inhalation) using the Visual Sonics Vevo 2100 Imaging System equipped with 
a 45 MHz MS-550D MicroScan transducer. Measurements and evaluation was performed 
by the SFB 1002 service unit S01 according to standard operating procedures in a blinded 
fashion as described previously [Zafiriou et al., 2014].
The evaluated parameters and their relationships with each other are listed in (Table 24).
Table 24. Echocardiographic parameters
Parameter short unit calculation
Length systole Ls mm measured directly
Length diastole Ld mm measured directly
Area systole Area s mm² measured directly
Area diastole Area d mm² measured directly
Anterior wall thickness systole AWThs mm measured directly
Anterior wall thickness diastole AWThd mm measured directly
Posterior wall thickness systole PWThs mm measured directly
Posterior wall thickness diastole PWThd mm measured directly
Epicardial area systole Epi s mm² measured directly
heart rate HR bpm measured directly
body weight BW g measured directly
fractional area shortening FAS % (Area d / Area s) / Area d x 100
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Table 26. Reagents used for qPCR (per well)
Reagent Amount
Sybr Green 2x Master mix 5 µl
CXR reference dye 0.1 µl
Primer fwd to 0.3 µmol/l
Primer rev to 0.3 µmol/l
Sample 1 µl cDNA (1:10) or ChIP sample
Water ad 10 µl
9 µl of each master mix were pipetted on a 384-well plate. Subsequently 1 µl of 1:10 diluted 
cDNA or Standard curve (10³ to 108 copies per µl) or ChIP sample was added per well.
Table 27. Program used for qPCR
Step Temperature Time
Initial denaturation 95°C 10 min
Denaturation 95°C 15 sec
Annealing + extension 60°C 1 min
Final extension 95°C 15 sec
Cycles 40
+ Dissociation stage 60°C - 95°C
Evaluation was done by quantification against the individual standard curve. 
7.3. Protein analysis
7.3.1. Protein isolation from cells / tissue
Protein isolation and immunoblots were done according to established protocols described 
e.g. in [Noack et al., 2019]. According to these protocols, protein was isolated from cells or 
tissue for determination of protein expression levels by immunoblot:
7.3.1.1. Isolation from cells
Medium was removed from the cell culture dish and the cells were washed with PBS. On ice, 
Bäuerle buffer (~100 µl per 1 million of cells) including inhibitors was added to the dish, then 
cells were scraped of and the buffer with cells was gently mixed at 4°C for 20 mins. Cells 
were disrupted by passing them 10 times through a 20 Gauge cannula. 
7.3.1.2. Isolation from mouse tissue
Bäuerle buffer (~500 µl for a third of a heart) with inhibitors was added to the frozen tissue. 
The tissue was disrupted into a homogeneous suspension using the tissue lyser. The homo-
geneous suspension was transferred to a fresh tube to remove the metal bead of the tissue 
lyser.
7.1.7. AAV-injections
Adeno-associated viral particles were produced and purified by the research group of Prof. 
Dr. Oliver Müller according to [Jungmann et al., 2017]. Briefly, the helper plasmid pDP9rs (a 
derivate of pDP2rs) was co-transfected with the respective AAV vector genome plasmid (ei-
ther pdsTnT-rluc or pds-TnT-mTBX5) in 293T cells. The obtained vectors AAV9-luc or AAV9-
TBX5 were subsequently purified by lodixanol step gradient centrifugation. To achieve re-ex-
pression of TBX5 in the vTbx5KO hearts, the mice received an intravenous injection of 2 x 
1012 viral particles similar to [Schwab et al., 2018]. The mice were subjected to short general 
anaesthesia with 1-2% isofluran inhalation. Then they received the injection of the viral par-
ticles in the tail vein with a 30-gauge cannula.
7.2. RNA analysis
7.2.1. RNA isolation
Total RNA was isolated using the RNA Isolation Kit according to manufacturers instructions. 
Concentrations were determined spectrophotometrically.
7.2.2. cDNA synthesis
To transcribe mRNA into copy DNA (cDNA) for quantification by quantitative PCR or amplifi-
cation by regular PCR, the following protocol was used according to manufacturers instruc-
tions:
Table 25. Reagents used for reverse transcription
Reagent Amount
OligodT (20x T) 500 ng/µl 1 µl
dNTPs (10mM) 1 µl
RNA 500 ng
Water ad 15.5 µl
Incubation at 65°C for 5 minutes
M-MLV RT 5x 4 µl
M-MLV RT (200u/µl) 0.5 µl
Reverse transcription for 50 min at 42°C
Enzyme inactivation by incubation for 15 min at 70°C
7.2.3. Quantitative PCR
Quantitative PCR with the SYBR Green dye was used for quantification of the expression of 
mRNA transcripts or ChIP samples according to manufacturers instructions. Master mixes 
with primers specific for the target sequence were prepared:
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Table 28. Paraffin embedding
Solution Incubation time
Roti-Histofix 24 hours, 4°C, rotating
Ethanol 70% until further processing, at least 72 h, 4°C
Ethanol 80% 30 min
Ethanol 90% 30 min
Ethanol 99% 30 min
Ethanol / Roti-Histol (1:1) 30 min
Roti-Histol 1 hour
Roti-Histol / Paraffin (heated) 1 hour
Paraffin (heated) over night, 60°C
After dehydration, sections were placed in molten paraffin (~60°C) and left to solidify at 
4°C over night. Thin (~5 µm) sections were cut with a microtome and placed on glass slides, 
which were store at 4°C until deparaffinisation. Deparaffinisation was carried out by a series 
of incubation steps in solutions to gradually rehydrate the sections (Table 29).
Table 29. Deparaffinisation
Solution Incubation time
Roti Histol 10 min (twice)
Ethanol 100% 10 min (twice)
Ethanol 96% 5 min (twice)
Ethanol 80% 5 min
Ethanol 70% 5 min
Water 5 min
PBS 5 min
10 mM Sodium citrate (pre-heated) 15 min in microwave at 180 W
Cooling for 20 min at room temperature
PBS 5 min (twice)
The rehydrated sections were used for immunostaining.
7.3.5. Immunostaining
Coverslips or slides were incubated with Blocking Buffer for one hour. Afterwards, the cov-
erslips were incubated with primary antibodies over night at 4°C. After washing 3 times 
with PBS for 10 minutes, the incubation with the secondary antibody (diluted 1:200, room 
temperature, 1 hour) followed. Next, the samples were washed three times with PBS for 10 
minutes, then stained with Nuclear Staining buffer for 5-10 minutes and washed 3 times for 
5 minutes with PBS and rinsed with water. Then the coverslips or slides were put on glass 
slides with Mowiol. Visualization was done with confocal microscope.
7.3.1.3. Clearing and Protein quantitation
Lysates were centrifuged for 20 mins at maximum speed (>10 000 x g). The supernatant was 
used for protein quantification and subsequent immunoblotting. To determine protein con-
centration, a 96-well Bradford assay against a standard curve of BSA with protein amounts 
ranging from 1 to 16 µg per well was performed.
7.3.2. Western Blot
Immunoblot analysis was performed to determine and quantify protein expression levels in 
protein lysates (7.3.1 describes preparation). Polyacrylamide gels for the SDS-PAGE were pre-
pared depending on the expected protein size (8-12% Acrylamide). Protein samples (50 µg 
for tissue lysates, 20-30 µg for cell lysates) were mixed with water and 4x Lämmli buffer and 
heated to 95°C for 5 min. After cooling, samples were loaded on the gel and electrophoresis 
was started. 
Gels were blotted on methanol-activated PVDF membranes by semi-dry transfer. To confirm 
blotting and protein loading, Ponceau staining was performed. Membranes were blocked 
with 5% milk powder dissolved in TBS-T and primary antibody incubation was carried out 
at 4°C over night under constant rotation. Membranes were washed three times with TBS-T 
and incubated with the corresponding secondary antibody coupled to horseradish peroxi-
dase for 1 hour shaking at room temperature. Subsequently membranes were washed three 
times with TBS-T and imaged in the Chemiluminescent imager after adding FemtoLucent.
If required, protein expression was quantified by densitometric analysis using the ImageLab 
software. Protein expression was normalized to GAPDH expression as a housekeeping pro-
tein as described previously [Zafiriou et al., 2014][Iyer et al., 2018].
7.3.3. Preparation of cells for immunostaining
Cells were washed 3 times for 2 minutes with PBS, then fixed by incubating with Roti-Hist-
ofix (4% PFA) for 15 minutes and washed 3 times for 5 minutes with PBS. Then they were 
incubated in Permeabilisation Buffer for 10 minutes at room temperature according to estab-
lished procedures described e.g. by [Zafiriou et al., 2014]. 
7.3.4. Preparation of tissue sections for immunostaining
Tissues were dehydrated for paraffin embedding with a series of solutions (Table 28) accord-
ing to established procedures described e.g. by [Zafiriou et al., 2014].
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7.4.1. PCR
For Cloning, Phusion polymerase was used according to manufacturers instructions.
Table 30. Reagents used for Phusion PCR
Reagent amount
HF buffer (5x) 4.0 µl
10 mM dNTPs 0.4 µl
primer fwd (10 µM) 1.0 µl
primer rev (10µM) 1.0 µl
template (ca. 200 ng/tube) x µl
water ad 20µl
Phusion 0.2 µl
Table 31. Program for Phusion PCR
Step Temperature Time
Initial denaturation 98°C 5 min
denaturation 98°C 30 sec
annealing primer specific 30 sec
extension 72°C 3 min
final extension 72°C 8 min
cycles 35
7.4.2. A-Tailing
The Phusion polymerase generates blunt end PCR products, but for subcloning in pGEM-T 
Easy a PCR product with A-overhangs is required. Therefore, fragments were A-tailed using 
DreamTaq Polymerase according to manufacturers instructions.
Table 32. Reagents used for A-Tailing
reagent amount
Phusion PCR product (directly) ad 10 µl
Dream Taq buffer 1.00 µl
dATPs 1.00 µl
DreamTaq 0.20 µl
The solution was incubated at 70°C for 30 minutes, the products were cleaned using aga-
rose gel electrophoresis followed by Gel extraction with a Kit according to manufacturers 
instructions.
7.4. Cloning
To validate putative enhancers found in the ChIP-Seq analysis, luciferase assays were per-
formed. The pGL4.25 vector was chosen, as it encodes a luc2CP reporter gene under the 
control of a minimal promoter. When an enhancer sequence is inserted upstream of the 
minimal promoter its activation by a transcription factor can increase luciferase expression, 
measurable in a multiwell-plate assay. To clone the enhancer fragments, murine genomic 
DNA was amplified with specific primers containing restriction sites for the multiple cloning 
site (MCS) of the pGL4.25 vector. The PCR product was A-tailed and ligated into the pGEM-T 
Easy subcloning vector according to manufacturers instructions, from which it could be re-
stricted and ligated in the final pGL4.25 plasmid (Figure 7).
Figure 7. 
1. Genomic DNA (mouse) A) Specic amplication and 
addition of restriction sites
B) Ligation into pGEM-T Easy 
subcloning vector
C) Restriction of the vector
D) Ligation in pGL4.25
2. PCR products with restriction sites
3. pGEM-T Easy with insert
4. Sticky end insert
5. pGL4.25 with enhancer inserted
Cloning of putative enhancers The enhancer sequence was amplified and restrictions sites were 
added by PCR. The resulting product was sub-cloned into the pGEM-T Easy vector. After restriction from 
this vector, the resulting fragment was ligated into the final pGL4.25 plasmid.
Tbx5, Gja1 and Kcnj5 plasmids for transfections and AAV-production were prepared in a 
similar manner, which has been previously described [Rathjens, 2015]. For transfections the 
pCMV2c-flag backbone was used, for AAV-production the pds-hTnnT-vector (provided by 
Oliver Müller, Heidelberg/Kiel) was used.
52 53
7.5. Cell culture methods
7.5.1. Transfection
HEK 293 cells were cultured in DMEM with 10% FCS and 1% Pen/Strep and passaged using 
0.05% Trypsin once or twice a week depending on confluency levels. Cells were plated on 
6-well-plates or 12-well-plates with coverslips coated with collagen on day 1. 24 hours later 
the DNA-Turbofect mixtures were prepared by mixing the plasmid, Turbofect™ and DMEM 
without FCS and Pen/Strep and incubating for 20 minutes. Then the cells were transfected 
by adding the mixtures. Four hours after applying the DNA/Turbofect mixture, medium was 
changed.
Table 34. Reagents used for Transfection for Luciferase assays (24-well plate)
reagent amount
plasmid DNA 500 ng
cells 100 000
Turbofect 2.0 µl
serum-free Medium 200 µl
total medium volume 1 ml
Table 35. Reagents used for Transfection for Western Blot (6-well plate)
reagent amount
plasmid DNA 3 µg
cells 500 000
Turbofect 6.0 µl
serum-free Medium 200 µl
total medium volume 4 ml
7.5.2. Isolation of neonatal rat cardiomyocytes and AAV6-transduction
Cardiomyocytes were isolated from neonatal rats (postnatal day 0 to 3). Hearts were excised 
and collected in Calcium and bicarbonate free Hanks with HEPES (CBFHH) after removal 
of atria (Table 21). The ‘Neonatal Heart Dissociation Kit mouse and rat’ was used to isolate 
neonatal rat cardiomyocytes (NRCM). Cardiomyocytes were separated from fibroblasts and 
other cells using a percoll gradient method. NRCMs were washed twice with NRCM medium 
and 1 million cells were plated in 6-well plates coated with collagen. Medium was changed 
every second day.
To transduce the NRCMs with AAV6-viruses encoding for TBX5, CX43 and GIRK4, the AAV6 
were added at a ratio of 100 000 particles per cell and left to incubate for 48 hours. Cells 
were harvested after 2 weeks of infection.
7.4.3. Ligation
Table 33. Reagents used for Ligation
reagent amount
insert (purified PCR product or restricted frag-
ment)
insert to vector ratio 3:1 to 9:1
vector 100 ng
10 x T4 Ligase buffer 2.00 µl
T4 Ligase 1.00 µl
water ad 20 µl
Ligations in pGEM-T Easy were incubated over night at 4°C, other ligations were incubated 
at 16°C over night or at room temperature for 1-2 hours.
7.4.4. Transformation
The NEB 10-beta competent Escherichia coli strain was used for transformations, unless sub-
sequent restrictions were predicted to be methylation sensitive, which made the use of dam-/
dcm- competent E. coli necessary. 
To transform bacteria with a ligation product, 5 µl of the ligation preparation (about 25 to 
50 ng of vector) were used. For a transformation with a validated plasmid, 1-2 µg of plasmid 
were used. The plasmids were gently mixed with 50 µl of the bacterial suspension and incu-
bated on ice for 30 mins. Afterwards a 45 sec heat-shock at 42°C was performed followed 
by incubation on ice for 2 mins. 450 µl of SOC medium were added and the bacterial sus-
pension was incubated for 1 h shaking at 37°C. This suspension was transferred to an agar 
plate containing the appropriate antibiotic for antibiotic selection and left to grow over night 
at 37°C.
7.4.5. Plasmid preparations
Small preparations (5 ml cultures) of plasmids were isolated using the plasmid purification 
kit mini; larger scale preparations (ca. 250 ml cultures) were purified with the Midi plasmid 
purification Kit according to manufacturers instruction.
7.4.6. Restriction
Restriction was done using FastDigest restriction enzymes according to manufacturers in-
structions. For restrictions intended for ligations, alkaline phosphatase was added to the 
restriction incubation of the plasmid. Fragments were analysed by gel electrophoresis, with 

















DNA for qPCR 
or Sequencing
 Schematic of Chromatin Immunoprecipitation Proteins binding to the chromatin are covalently 
cross-linked. Afterwards the chromatin is sheared into fragments of the correct size and nuclei are lysed. 
Immunoprecipitation enriches for fragments bound to a specific protein. The immunoprecipitated DNA is 
cleared and can be used for analysis by qPCR or next-generation sequencing.
7.6.1. Cross-linking
Fresh murine cardiac ventricles, prepared as described (7.1.5 for details), were dissected and 
incubated in 2% FA in PBS (1 ml for one ventricle) for 30 min constantly moving. Cross-link-
ing was quenched by addition of glycine to a final concentration of 125 mmol/l with sub-
sequent incubation for 5 min. Samples were centrifuged at 300 x g at 4 °C for 5 min. The 
supernatant was discarded and the pellet was washed with PBS (1 ml for one ventricle) 
containing protease inhibitors for 5 min. After centrifuging again, the supernatant was re-
moved and the pellet was snap-frozen in liquid nitrogen and stored at -80°C or immediately 
proceeded with nuclei isolation.
7.6.2. Nuclei Isolation
To each ventricle, 500 µl of hypotonic buffer were added and the tissue was meshed in the 
tissue lyser for about 6 min at 30 Hz. This was incubated on ice for 5 min, NP-40 was added 
to a final concentration of 1 %, transferred to a fresh tube and incubated on ice for 10 min. 
Centrifugation was done at 12 000 x g and 4°C for 2 min, the supernatant was discarded. 
The pellet was resuspended in 500 µl of hypotonic buffer with 1% NP-40 and incubated on 
ice for 3 min. After another centrifugation for 3 min, the supernatant was discarded and the 
pellet was snap-frozen or immediately proceeded with sonication.
7.6.3. Sonication
To each ventricle, 750 µl of Sonication buffer I were added to resuspend the pellet, followed 
by 15 min incubation on ice. Secondly, 750 µl of Sonication buffer II were added and the mix-
ture was distributed in 6 TPX tubes (250 µl each) for sonication. Samples were sonicated for 
30 cycles with 30 sec ON/OFF and centrifuged at 8°C, 12 000 x g for 10 min. The superna-
tant was kept as chromatin fraction I. The pellet was resuspended in 750 µl Sonication buffer 
I and 750 µl Sonication buffer II and again distributed in 250 µl each in TPX tubes. Sonication 
and centrifugation were repeated and the supernatant was kept as chromatin fraction II for 
chromatin immunoprecipitation.
7.5.3. Isolation of murine adult cardiomyocytes
Adult hearts were excised as described (7.1.5 for details) and blood was removed in ice-cold 
PBS. The heart was transferred into ice-cold perfusion buffer and a blunt-end 20 G cannula 
was inserted into the aorta. The aorta was fixed on the cannula with surgical yarn and slowly 
perfused to verify correct placement. The heart was connected to a Langendorff perfusion 
system for continuous retrograde perfusion at a flow rate of 4 ml/min at 37°C. Perfusion was 
done for 1 min with perfusion buffer, then 8-9 min with digestion buffer. After digestion, 
hearts were removed and ventricles were minced. The suspension was further homogenized 
by carefully pipetting up and down in stopping buffer. To remove bigger undigested frag-
ments suspension was left for 1 min and supernatant containing cells was transferred to a 
fresh tube. To enrich for cardiomyocytes, the suspension was left to sediment by gravity for 8 
min. This step was repeated 3 times using increasing Ca2+ concentrations. Supernatants were 
collected as non-myocyte fraction. For cardiomyocyte culture, sedimented cardiomyocytes 
were plated on laminin-coated glass cover slips and incubated for 1 hour at 37°C before 
fixation (7.3.3 for details).
7.5.4. Luciferase assays
Luciferasse assays were performed 24 hours after transfection according to manufacturers 
instructions. In brief, cells were lysed using the Passive Lysis Buffer. 20 µl of this lysate were 
transferred to a white 96-well plate and the assay was performed in the Luminometer. Firstly, 
Firefly Luciferase activity was measured, followed by Renilla activity detection for normalisa-
tion. Luminescence values of the Firefly were divided by Renilla and normalized to the condi-
tion without the enhancer and the empty pCMV2c-plasmid.
7.6. Chromatin Immunoprecipitation
To determine the binding sites of transcription factors or other DNA-binding proteins on 
native DNA, the technique of Chromatin Immunoprecipitation (ChIP) can be used. This tech-
nique consists of four basic steps (Figure 8): Firstly, the chromatin is covalently cross-linked 
to associated proteins. Secondly, the chromatin is sheared into fragments of an optimal size 
of 200 - 1000 bp, depending on downstream applications. The sheared chromatin can be 
immunoprecipitated with an antibody directed towards the protein of interest. After immu-
noprecipitation the DNA is isolated. It can be analysed by quantitative PCR for specific loci 
or subjected to next-generation sequencing for an unbiased approach. As controls, immu-
noprecipitation with an IgG control or total input (non-immunoprecipitated chromatin) can 




Basic ChIP-Seq analysis was performed on Galaxy [Afgan et al., 2016] on usegalaxy.org. 
In brief, the sequence reads were aligned to the mouse reference assembly (UCSC version 
mm9) using Bowtie [Langmead, 2010]. Model Based Analysis of ChIP-Seq (MACS2) version 
2.1.0.20140616.0, which is the updated version of MACS [Zhang et al., 2008] was used for 
peak calling; IgG was used as a control file. Bedgraphs obtained from MACS2 were con-
verted to bigwigs and visualized using the Integrative Genomics Viewer IGV 2.3.82 [Thor-
valdsdóttir et al., 2013][Robinson et al., 2011]. To calculate the enriched genomic regions 
in the TBX5-ChIP-Seq dataset ‘CEAS: cis-regulatory element annotation system’ [Shin et al., 
2009] was used on Cistrome [Liu et al., 2011]. GREAT analysis was performed to annotate 
the peaks to genes and calculate enrichment of gene ontology clusters for biological pro-
cesses and human phenotypes for TBX5 [McLean et al., 2010]. Heatmaps were generated 
using deepTools-computeMatrix and heatmapper options for the ChIP-Seq signal (in RPKM) 
using bamCoverage [Ramírez et al., 2014]. Co-Occupancy correlation was statistically ana-
lyzed with multibigwig summary and plot correlation on Galaxy. To identify TBX5-peaks, 
that are overlapping with H3K27ac and POL2, the WindowBed function (500 bp up- and 
downstream) from BEDTools was used in Galaxy [Björn Grüning et al., ][Quinlan et al., 2010]. 
Motif Enrichment in the ChIP-Seq dataset was tested with AME [McLeay et al., 2010] using 
known motifs for TBX5, MEIS1 and MEIS2, GATA4 and NKX2.5. Motifs used were identified 
from previous studies [Ghosh et al., 2001] [Grau et al., 2013] and MotifMap [Daily et al., 
2011] [Xie et al., 2009]. De novo motif discovery was carried out using HOMER [Heinz et 
al., 2010].InteractiVenn [Heberle et al., 2015] was used to analyse the intersection between 
TBX5 bound genes (found in ChIP-Seq) and genes differentially expressed in TBX5 KO ven-
tricle (cutoff p<0.05; Log2-fold-change >0.8 or <-0.8 respectively). Gene ontology/pathway 
analyses were performed using a minimum of 4 genes per cluster and default parameters 
and stringency in ‘ClueGO’: a Cytoscape plug-in [Bindea et al., 2013][Bindea et al., 2009] 
and the significant (p ≤ 0.05) cluster of ‘Gene Ontology Biological Processes’ were shown.
7.8. Statistical analysis
All data are displayed as individual values with mean (indicated by the line) or as box-and-
whisker plot with the box extending from the 25th to 75th percentile, whiskers indicating 
min to max, + indicates the mean value and the line indicates the median. The statistical tests 
that were used are indicated in each figure legend.
Differences were considered statistically significant, when p value was below 0.05.
7.6.4. Shearing check
As a quality control, the fragment size after shearing was controlled by gel electrophoresis 
after elution. Therefore 10 µl of chromatin were incubated with 30 µl IP Elution buffer, 1.2 
µl of 5 mol/l NaCl and 0.4 µl of Proteinase K (8 µg) shaking at 65°C for 1.5 hours. 12.5 µl 
of this mixture were added to 2.5 µl of loading dye (6x) and analysed on a 1% agarose gel.
7.6.5. ChIP
For each ChIP 350 µl chromatin fraction II, 1.4 ml ChIP Incubation buffer, 35 µl Protease 
Inhibitors (40 x stock) and 1.27 µg of antibody were incubated rotating at 4°C over night. 
The next day 35 µl ChIP grade Protein A/G magnetic beads were added and incubation was 
continued for 2 hours. Subsequently, the beads were washed with 1.2 ml of Wash Buffers 1 
(once), 2 (three times) and 3 (once) for 5 min each rotating at room temperature.
7.6.6. Elution
To elute the DNA from the beads, a Proteinase K incubation was used to enzymatically re-
move the proteins from the solution. Each sample of beads was supplemented with 250 µl 
ChIP Elution buffer, 10 µl 5 mol/l NaCl and 3.33 µl of Proteinase K (67 µg). The input sample 
was prepared correspondingly from 35 µl chromatin fraction II, 150 µl ChIP Elution buffer, 
6 µl 5 mol/l NaCl and 2 µl of Proteinase K (40 µg). Samples were vortexed and incubated at 
65°C for 1.5 hours with vigorous shaking.
7.6.7. DNA recovery
The PCR and Gel Clean Up Kit was used with Buffer NTB for SDS-containing samples accord-
ing to manufacturers instructions.
7.6.8. Analysis
Quantitative PCR was done as described (7.2.3). The sample quantities were calculated by 
regression from standard curves for each primer. The % input values were calculated by di-
viding the IP quantity by the 10% input value and multiplied by 10. The fold-enrichment was 
calculated by dividing the IP value by the corresponding IgG control.
Next-Generation Sequencing was carried out by the NGS Integrative Genomics Core Unit 
of the University Medical Centre Göttingen. In brief, ChIP-Seq library preparation was per-
formed using NEBNext Ultra DNA library prep kit for Illumina (E7370) according to manu-
facturer’s instructions. Quantitation of DNA libraries was done on an Invitrogen Qubit 2.0 
Fluorometer and the size range of DNA libraries was performed on an Agilent Bioanalyzer 
2100 (High Sensitivity DNA Assay). DNA libraries were amplified and sequenced by using 
cBot and HiSeq2500 from Illumina (20-25 million reads per sample).
58 59
8.2. Cardiac function of TBX5 KO mice
Since the mice had a cardiac deficiency of Tbx5, we aimed to observe, if the decreased sur-
vival rate was due to functional impairments of the heart by echocardiography and electro-
cardiography.
8.2.1. Echocardiography
8.2.1.1. Absence of physiological hypertrophy
The heart dimension and function of Flox, Cre and KO mice were analysed by echocardiog-
raphy prior and 8 and 16 weeks after recombination. Firstly, the heart grew physiologically in 
the Cre group along with the increase in body weight (BW), resulting in an unchanged heart 
weight to body weight ratio (HW/BW) (Figure 10A-C). In contrast to the Cre group, the heart 
weight (HW) in the vTbx5KO group did not change over time, although the body weight 
increased in a comparable manner (Figure 10A-B). This results in a reduced HW/BW ratio at 
8 and 16 weeks after recombination (Figure 10C).
Figure 10. 








































Flox Cre KO Flox Cre KO Flox Cre KO
* ** **
* *
Tbx5 KO leads to reduced heart growth  Echocardiographic analyses was performed before 
and 8 and 16 weeks after induction. A. Whereas the heart weight (HW) increases over time in the Cre con-
trol group, it does not change in the KO group. B-C. Since body weight increases normally in all groups, 
the heart weight to body weight ratio (HW/BW) in the KO group decreases. Statistics: Two-Way ANOVA, 
followed by Sidak’s Multiple Comparison Test * p<0.05
8.2.1.2. Diastolic dysfunction in the absence of TBX5
Analysis of the cardiac contractile function revealed a reduction of fractional area shorten-
ing (FAS) and ejection fraction (EF) 16 weeks after recombination (Figure 11A-B). The stroke 
volume (SV) decreased over time in the KO hearts (Figure 11C), resulting from the decreased 
volume in diastole (Figure 11D). In contrast, the volume in systole remained unchanged (Fig-
ure 11E). Hence, cardiac output (CO) and cardiac index (CI) are as well decreasing over time 
(Figure 11F-G). Diastolic thickness of the anterior and posterior walls of the left ventricle did 
not change significantly in any group over time (Figure 11H-I).
8. Results
8.1. Ventricular specific KO of TBX5
To characterize the effects of TBX5 in the adult heart, we used an inducible cardiomyo-
cyte-specific loss-of-function mouse model [Renger, 2012] (7.1.1 for details). Recombination 
was confirmed by quantitative PCR for Tbx5 mRNA. As expected, endogenous expression 
of Tbx5 was stronger in the atria than in the ventricles. Surprisingly, recombination occurred 
robustly in the ventricles 4 weeks after induction, but no changes in the Tbx5 expression 
levels in the atria could be observed (Figure 9A). Flox mice (Tbx5LDN/LDN without Cre) and Cre 
mice (Myh6-MerCreMer with homozygous wild-type alleles of Tbx5) injected with Tamox-
ifen served as control animals throughout the study. Neither Flox nor Cre mice showed any 
incidence of death in the months after recombination, whereas 60% of vTbx5KO mice died 
without showing any prior symptoms of disease (Figure 9B).
Figure 9. 
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A ventricular specific KO of Tbx5 results in a decreased survival rate A. Recombination of Tbx5 
was confirmed on mRNA level by quantitative PCR. Whereas the Tbx5 levels strongly decreased in the 
ventricles, they remained unchanged in the atria, indicating ventricular specific recombination. B. The 
survival rate of vTbx5KO mice is severely decreased; after 5 months of recombination 40% of the mice are 
still alive. Statistics: * p<0.05 A. Unpaired students t-test in the atria and ventricle groups B. Differences in 
the survival rate were tested by logrank test (Mantel-Cox)
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8.2.2. Electrophysiological properties of vTBX5KO hearts
Telemetric ECG recordings over 24 hours before and one, two and four weeks after recom-
bination show, that vTbx5KO mice have slower signal propagation compared to Flox and 
Cre control mice (Figure 12A). Statistical evaluation revealed increasingly longer PR, QRS and 
QT-intervals beginning from 1 week after recombination (Figure 12B). Along with this sta-
tistical variation of the cardiac cycle, mice showed different arrhythmias, like atrioventricular 
block, ventricular tachycardia and even asystoles (Figure 13), that could be causative of the 
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Timecourse analysis of ECG parameters shows gradual prolongation of PR- and QRS-intervals in 
vTbx5KO mice A. Representative ECG-traces of Flox and KO mice B. Time course evaluation of PR and QRS 
intervals revealed a prolongation of both conduction parameters over a course of 4 weeks in the TBX5 KO 
mice. Statistics: B: one-way ANOVA with Sidak’s multiple comparison test; p-value-summary: * without 
lines - <0.05 for a comparison with the respective time point of Flox and Cre, as well as to the 0 week time 
point of the vTbx5KO . n=4-13/group. * with lines - <0.05 for the indicated comparison. 
Figure 11. 





















































































































Flox Cre KO Flox Cre KO Flox Cre KO
Flox Cre KOFlox Cre KO Flox Cre KO







TBX5 KO leads to diastolic dysfunction Echocardiographic analyses was performed before and 
8 and 16 weeks after recombination. A-C. Fractional area shortening (FAS), Ejection Fraction (EF) and 
Stroke volume (SV) are decreasing in the KO group. D-E. In contrast to the Volume in systole (Vol s), the 
Volume in diastole (Vol d) decreases over time in the KO group. F-G. Cardiac output (CO) and Cardiac 
index (CI) decrease over time in the KO group. H-I. The wall thickness in diastole of the anterior (AWThd) 
and posterior (PWThd) wall of the left ventricles remains unchanged in all groups. Statistics: Two-Way 

























































































































vTbx5KO hearts show slower signal propagation A. Ex vivo S2 pacing induced arrhythmia oc-
currence is higher (60%) in vTbx5KO mice vs Flox (23%) and Cre (38%) mice, although the level did not 
reach statistical significance B. Electrophysiological studies of isolated paced Flox, Cre and vTbx5KO 
hearts show prolonged activation times from right atrium (RA) to right ventricle (RV), endocardial RV to 
epicardial RV, RV to septum and RV to left ventricular epicardium (LV). C. Action potentials in the right and 
left ventricle were not different between the groups. APD90 measured at a cycle length of 100 ms. Statis-




























vTbx5KO mice develop ventricular and supraventricular arrhythmias A. Red trac-
es show vTbx5KOmice experiencing third degree atrioventricular (AV) block, ventricular 
tachycardia (B) and sinus pauses (C).
More detailed electrophysiologic evaluation by ex vivo analysis (carried out by 
Fahima Syeda, Nashita Kabir and Larissa Fabritz, Birmingham) of the heart con-
firmed a tendency of increased arrhythmic activity in the vTbx5KO hearts upon 
S2 pacing (Figure 14A). Furthermore, these mice had longer activation times 
from right atrium to right ventricle, inside the right ventricle and from right 
ventricle to septum and left ventricle (Figure 14B), confirming the slower signal 
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Establishment of the TBX5-ChIP-Seq A. Optimization of Chromatin Fractionation by Sonication: 
Fraction II, sonicated for 30 cycles was chosen for further experiments. B. ChIP-qPCR for the Scn5a en-
hancer revealed enrichment in the anti-TBX5 sample vs. the IgG sample. C. Sequencing showed a peak for 
the Scn5a enhancer in the TBX5-ChIP-Seq. The location of the PCR product from B is depicted in purple. 
Statistics: B: unpaired students t-test, * p < 0.05.
8.3. Chromatin binding of TBX5
To understand the underlying molecular mechanisms of the electric and contractile dysfunc-
tion in the absence of TBX5, we aimed to identify ventricular TBX5 target genes. Therefore 
we integrated chromatin binding sites from a TBX5 ChIP-Seq with dysregulated genes de-
tected by RNA-Sequencing from vTbx5KO vs control ventricles.
8.3.1. Establishment of Chromatin Immunoprecipitation for TBX5 in adult hearts
The chromatin immunoprecipitation (ChIP) procedure was established to enable detection 
of new TBX5 binding sites on the chromatin in the adult mouse ventricle. In the process, 
an important step was to optimize the fractionation of the chromatin. An optimal size are 
chromatin fragments around 200-300 bp [Johnson et al., 2001]. Nuclei were sonicated for 
30 cycles and the supernatant was collected, the remaining nuclei were re-sonicated for 30-
55 cycles and the supernatant was again collected (7.6.3 for details). The supernatant of the 
first round contained Chromatin Fraction I, the supernatant of the second round Chromatin 
Fraction II (Figure 15A). It was chosen to use the chromatin from fraction II, sonicated for 30 
cycles for further ChIP-Experiments because of optimal fragment size. Indeed, after Chroma-
tin Immunoprecipitation, the size of precipitated chromatin analysed on the Bioanalyzer was 
303 bp on average (ranging from 179 - 471 bp, n=3, used for sequencing). 
To verify the success of the ChIP itself, we examined binding to the previously established Sc-
n5a enhancer [Arnolds et al., 2012]. Quantitative PCR of the TBX5 precipitated DNA showed 
a reproducible enrichment on this enhancer (Figure 15B). 
The obtained chromatin samples with a controlled fragment size and a validated enrichment 
of the Scn5a enhancer were subjected to next generation sequencing. A series of bioinfor-
matic analysis was performed (7.7 for details). The enrichment of the Scn5a enhancer could 
be confirmed in the sequencing results from the TBX5-ChIP as well (Figure 15C, red traces).
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To gain information about the genomic regions a transcription factor 
binds to, it can be evaluated in what distance to a transcription start site 
the ChIP-Seq peaks are located, an information that can be obtained 
using GREAT analysis [McLean et al., 2010]. However, the information 
which types of genomic regions (e.g. promoter, exon, intron) are bound 
by TBX5 provides a more sophisticated insight into the binding properties. 
Therefore an analysis with CEAS (cis-regulatory element annotation sys-
tem) [Shin et al., 2009][Liu et al., 2011] was done. The binding patterns 
of TBX5 (Figure 16A - left panel) were then compared to the genomic 
background (Figure 16A - right panel). Compared to the genomic back-
ground an enrichment of promoter, 5’UTR, intronic regions and regions 
downstream to the gene body was found for the TBX5 bound regions 
(Figure 16A). 
Next, we compared our TBX5 data to published data using deeptools 
[Ramírez et al., 2016]. We were interested in overlaps with marks of 
active enhancers (H3K27ac and POL2) [van den Boogaard et al., 2012] 
to determine whether TBX5 acts transcriptionally activating in the adult 
ventricle. Additionally, we studied peaks of the transcription factors 
NKX2.5 and GATA4, which are known to bind cooperatively with TBX5, 
and of TBX3 [He et al., 2014], known to bind to similar regions as TBX5. 
Indeed, we found a co-occupancy for the active enhancers as well as for 
the aforementioned transcription factors (Figure 16B and C). 
Furthermore, we analysed the gene ontology annotations for genes 
bound by TBX5 in our ChIP-Seq dataset and found heart contraction 
and muscle development related biological processes and human disease 
phenotypes like arrhythmia and cardiomyopathy being overrepresented 
(Figure 16D and E).
Figure 16. 
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TBX5 co-occupies active enhancers with NKX2.5 and GATA4 A. Analysis of enriched genomic 
locations of TBX5-ChIP shows that TBX5 preferably binds to promoter sites, downstream of the gene body, 
in the 5‘ UTR and intronic regions (CEAS package[Shin et al., 2009], [Liu et al., 2011] on Cistrome). B/C. 
TBX5 bound regions show high co-occupancy with marks of active enhancers (H3K27ac, POL2) [He et al., 
2014], known cofactors (NKX2.5, GATA4) and TBX3 [van den Boogaard et al., 2012]; analysed data from 
previously published datasets. Results are displayed in B as the statistical analysis of co-occupancy show-
ing Pearson’s correlation coefficients and in C as heatmaps using deeptools [Ramírez et al., 2016] in Gal-
axy. The scale bar in B depicts co-occupancy percentage and in C normalized RPKM values. D. TBX5-
bound regions were annotated to genes using GREAT [McLean et al., 2010]. These regions were analysed 
for the 10 most enriched biological process clusters (D) and the 10 most enriched human disease pheno-
type clusters (E) of TBX5 peaks.
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However, there are 500 peaks that are more than 2-fold enriched in the adult and 424 in 
the embryonic dataset. 122 peaks show similar binding patterns in the adult and embryon-
ic stage. When these sets of differentially bound peaks were annotated to genes and the 
corresponding ontologies using GREAT [McLean et al., 2010], the adult peaks seem to be 
associated to cardiomyocyte homoeostasis and the embryonic to cardiomyocyte differentia-
tion and development (Figure 17C-D). Common peaks are annotated to ventricular cardiac 
muscle tissue development and cardiac muscle contraction (annotation was performed with 
ClueGO [Bindea et al., 2013][Bindea et al., 2009] instead of GREAT due to the lower number 
of genes).
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Integrative chromatin occupancy and transcriptome analysis identified clusters of novel puta-
tive TBX5 downstream targets in the adult ventricle A. RNA-Sequencing results displayed in a volcano plot. 
97 genes are down- and 93 are upregulated in vTbx5KO ventricles using a cut-off of p<0.05 and log2-fold-
change of > 0.8 or < -0.8. B. TBX5 co-occupancy with marks of active enhancers H3K27ac and POL2 iden-
tified 2,046 putative TBX5 active enhancers. These were annotated to genes with GREAT (Gja1 and Fgf16 
enhancers were not annotated automatically by GREAT, but manually identified by BED file analysis in the 
IGV platform). Venn-diagram showing the intersection of those genes with the regulated transcripts of the 
RNA-Seq analysis. C. Gene ontology analysis of biological processes for 47 ventricular TBX5 targets.
In addition to the TBX5-ChIP-Seq, we performed RNA-Sequencing of vTbx5KO hearts vs. 
control hearts to determine which genes are differentially regulated in the absence of TBX5. 
This revealed 97 down- and 93 upregulated genes in the vTbx5KO mice (Figure 18A). The 
8.3.2. TBX5 chromatin occupancy in the adult vs. the embryonic heart
As described, we performed ChIP sequencing in murine adult hearts. Since comparisons 
of ChIP-Seq datasets from different tissues or developmental stages can give insight into 
context-depent action of a transcription factor, we decided to perform a differential bind-
ing analysis. Therefore, we compared our dataset with a recently published ChIP-Seq for 
TBX5 in murine hearts from stage E9.5 [Steimle et al., 2018]. Both datasets are distinctly 
different based on principal component analysis (PCA) (Figure 17A). Nevertheless, when the 
E9.5 peaks were mapped to the regions bound by TBX5 in the adult heart using deeptools 
[Ramírez et al., 2016][Ramírez et al., 2014], embryonic TBX5 peaks showed an enrichment 
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Comparison of adult and embryonic TBX5 ChIP-Seq A. Principal Component Analysis shows that 
the two embryonic and two adult ChIP-datasets cluster together. Analysis was performed by the DiffBind 
Package on differentially bound sites [Ross-Innes et al., 2012]. B. Summary and heatmap created with 
deeptools [Ramírez et al., 2016][Ramírez et al., 2014], showing that TBX5-peaks from the embryonic data-
set are enriched on the adult dataset. C-D. DiffBind was also used to determine the differentially bound 
peaks of the adult and embryonic dataset (Cut-Off: 2-fold enrichment in each dataset). These peaks were 
annotated to genes and gene ontologies using GREAT [McLean et al., 2010]. Whereas the adult TBX5 target 
genes (C) bind to genes relevant for contraction and conduction, the embryonic genes (D) are associated 
with differentiation and developmental processes.
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We performed quantitative PCR to determine the mRNA expression in vTbx5KO hearts com-
pared to Flox and Cre hearts. We indeed found each transcript to be downregulated in the 
vTbx5KO hearts (Figure 19B). Furthermore, CX43 (encoded by Gja1) and GIRK4 (encoded 
by Kcnj5) showed reduced expression on protein level as well (Figure 20A). Immunofluores-
cence analysis of cross-sections of the ventricular myocardium showed that CX43 is strongly 























































































































 Gja1 and Kcnj5 are transcriptionally regulated by TBX5 A. Immunoblot analysis of CX43 (encod-
ed by Gja1), GIRK4 (encoded by Kcnj5) and GAPDH shows a strong downregulation of CX43 and GIRK4 in 
vTbx5KO mice. Representative blot of n=6 per group. B. CX43 expression is strongly reduced in the ven-
tricle of vTbx5KO mice shown by immunofluorescence staining for CX43 (red) and cTNT (green). Scale 
bars: 50 µm. C. The putative enhancers for Gja1 (upstream) and Kcnj5 (downstream) identified by ChIP-
Seq are co-occupied by H3K27ac, POL2, NKX2.5, GATA4 and TBX3. D. Scheme indicating 3 predicted T-box 
elements (TBE) in the enhancer sequences for Gja1 and Kcnj5. E. Gja1 and Kcnj5 enhancer activity analysis 
by luciferase measurements show enhancement of luciferase expression by TBX5 co-transfection. Statis-
tics: ; E: unpaired, two-tailed student’s t-test, p-value-summary: * - <0.05
We found a putative enhancer for Gja1 ~600kb upstream of the TSS and for Kcnj5 700 bp 
downstream of the last exon. A closer look on the TBX5 ChIP-Seq results of the putative 
Gja1 and Kcnj5 enhancers showed a TBX5 peak consistent with NKX2.5, GATA4 and TBX3 
ChIP results. These peaks were also marked as active by H3K27ac and POL2 occupancy (Fig-
upregulated genes are related to blood coagulation/platelet aggregation (Ifi204, Ifit1/2, 
Gm4951) and cellular response to interferon-alpha/beta (Fermt3, Itga2b, Plek, P2ry12, F5, 
Gp9, Hpse). Because these processes have little link to the phenotype of the vTbx5KO mice 
besides frequent blood clots in the atria, we decided to focus on the downregulated genes. 
To narrow down the number of peaks from the TBX5-ChIP-Seq relevant for the downregu-
lated genes, we chose only the peaks that were marked as active enhancers by co-occupancy 
of H3K27ac and POL2. Of these 2046 genes, 47 were downregulated in the vTbx5KO model 
(Figure 18B). Gene ontology analysis for biological processes of these 47 genes revealed an 
enrichment of clusters relevant in muscle development, contraction and ion transmembrane 
transport (Figure 18C). 
Validation of novel TBX5 target genes
Of those 47 genes we chose 12 genes, due to their (putative) role in cardiac electrophysiol-
ogy (Gja1, Kcnj5, Kcng2, Cacna1g, Chrm2), cardioprotection (Fhl2, Gpr22, Fgf16) and con-
traction (Fstl4, Cmya5, Emilin2, Pdlim4) for further validation. The corresponding peaks from 

































































































 Validation of identified genes regulated in vTbx5KO A. Visualisation of TBX5 peaks on selected 
downregulated genes using IGV. The TBX5-ChIP-Seq is displayed in red and gene features in blue. The 
peaks investigated further are indicated in green. The y-axis represents the treatment pileup peak summit 
scores B. Validation of target gene expression by qPCR (Flox, light grey; Cre, dark grey; vTbx5KO, red) 
Statistics: B. One-way ANOVA for each transcript followed by Tukey’s multiple comparison test * p < 0.05 
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Validation of the next generation sequencing by qPCR and immunoblot analysis showed that 
Armh4 expression in the mouse heart is significantly diminished on mRNA and protein level 
upon cardiomyocyte specific KO of TBX5 (Figure 21A-B). We analysed the chromatin-binding 
of TBX5 around the Armh4 gene with the TBX5-ChIP-Seq data and revealed two putative 
TBX5-binding sites upstream of Armh4 (Figure 21C). Both putative enhancers are bound by 
POL2 and H3K27ac marking active enhancers as well as by TBX3, NKX2.5 and GATA4 which 
are known to co-occupy chromatin together with TBX5.
In order to get some insight in the function of this protein in the heart, we performed im-
munostaining in isolated adult murine cardiomyocytes. ARMH4 is mainly localized at the 
Z-discs (white arrowheads), where it co-localises with alpha-actinin expression, intercalated 
discs (yellow arrows) and around the nuclei (Figure 22) similarly to sodium channels [Haufe 
et al., 2005]. 
In conclusion, the sub-cellular distributions as well as the structure of ARMH4 lead us to 
the hypothesis that it could be part of a membrane protein complex. Since it is found to be 








ARMH4 is localized mainly at the intercalated discs and z-discs of adult mouse cardiomyo-
cytes. Sub-cellular distribution of ARMH4 protein in adult mouse CMs. A+B. ARMH4 (red) is expressed at the 
striations (white arrowheads) and at the intercalated discs (yellow arrows) of cardiomyocytes in the adult 
mouse heart. C+D. Isolated CMs co-stained for cTNT (green, C) and α-actinin (green, D) showed ARMH4 to 
be expressed mainly at the intercalated discs and Z-discs. Scale bar: 50 µm (panels A+B); 20μm (panels C 
+ D) 
ure 20C). Both enhancers harbour 3 potential T-box binding elements (TBE) (Figure 20D). 
We cloned these enhancers in a plasmid upstream of a firefly luciferase coding sequence 
with a minimal promoter. This plasmid has a low basic luciferase expression, that can be in-
creased, when a co-expressed transcription factor activates the inserted enhancers. Indeed, 
co-expression with TBX5 led to a strong increase of luciferase, indicating TBX5 can bind and 
activate both enhancers (Figure 20E).
8.4.1. Armh4
Among the described targets, which functions are mostly known, one of the most down-reg-
ulated targets in the vTbx5KO hearts was  armadillo-like helical domain containing 4 (Armh4). 





















































50.402 kb 50.404 kb 50.406 kb 50.408 kb 50.410 kb 50.412 kb 50.414 kb
14 kb
chr14
qA1 qA2 qA3 qB qC1 qC2 qC3 qD1 qD2 qD3 qE1 qE2.1 qE2.2 qE2.3 qE3 qE4
TSS
C
Armh4 is downregulated on mRNA and protein levels in vTbx5KO hearts A. Transcript levels were 
analysed by qPCR and were normalized to the housekeeping gene TATA-binding protein (Tbp). B. Immu-
noblot was performed against ARMH4 (upper panel) and normalized to CASQ2 (lower panel). *This Flox 
mouse although it was not recombined, had low TBX5, GIRK4 and CX43 expression. C. TBX5 binds strong-
ly to putative enhancers upstream of Armh4, indicated by ChIP-Seq also from POL2, H3K27ac, TBX3, 
NKX2.5 and GATA4 of data publicly available [He et al., 2014]; [van den Boogaard et al., 2012]. 
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Therefore, we included MEIS1 and MEIS2 motifs along with motifs of TBX5, NKX2.5 and 
GATA4 in the AME analysis, which was applied on the total number of TBX5 peaks and for 
the subset of TBX5 enhancer peaks overlapping with H3K27ac- and POL2-occupancy. For 
the dataset of the total TBX5 peaks, again MEIS1 motif achieved the highest significance, 
whereas in the dataset of the TBX5 enhancer peaks a known motif of TBX5 itself showed the 
highest significance (Table 36). 
Table 36. Motif analysis in TBX5-ChIP-Seq peaks 







MEIS1 NHNTGACAGNNN 5.32 x 10-174 3.92 x 10-18 MotifMap
TBX5 RGGTGTBR 1.06 x 10-148 9.91 x 10-43 [Ghosh et al., 2001]
TBX5 NDAGGTGTBRNN 1.61 x 10-113 1.53 x 10-35 MotifMap
TBX5 TNACACCT 6.26 x 10-92 8.21 x 10-21 [Grau et al., 2013]
MEIS1 NDNBASCTGTCAWWNN 9.99 x 10-78 9.16 x 10-09 MotifMap
GATA4 AGATADMAGRSA 7.42 x 10-74 7.92 x 10-09 MotifMap
MEIS2 NDNBASCTGTCAAWNN 6.33 x 10-60 2.37 x 10-05 MotifMap
GATA4 ARAWWDMRGRSA 8.85 x 10-40 7.92 x 10-07 MotifMap
TBX5 BNDGGTGTKV 5.61 x 10-32 1.54 x 10-15 MotifMap
TBX5 YTCACACCTK 2.91 x 10-19 1.14 x 10-04 MotifMap
TBX5 DGGTGYBV 1.71 x 10-14 6.19 x 10-07 [Ghosh et al., 2001]
TBX5 SGGCGCCKS 7.08 x 10-04 8.22 x 10-03 [Grau et al., 2013]
NKX2.5 WTAAKWK 6.75 x 10-03 MotifMap
NKX2.5 YBYCACTTSM 4.28 x 10-03 MotifMap
These findings led us to take a closer look at MEIS1 targets. When comparing MEIS1 ChIP-
Seq data publicly available from murine embryonic trunk to TBX5 ChIP-Seq data, MEIS1 
shows some overlap with the TBX5 peaks (Figure 24A - analysis run by Lavanya Iyer). The 
overlapping peaks are related to regions annotating to cardiac morphogenesis and function 
(Figure 24B).
To gain more insights on the relationship between TBX5 and MEIS in the adult heart we per-
formed ChIP-qPCRs for TBX5 and MEIS1 on different TBX5 targets (8.4 for information on 
the selected targets) in control and KO mice (ChIP and qPCRs were performed by Lavanya 
Iyer). We firstly found that no target sequence was bound by TBX5 in the vTbx5KO hearts 
(Figure 24C), thereby validating the newly identified targets.
8.5. Novel TBX5 co-factor in TBX5
Common analysis of ChIP-Seq data includes motif analysis, which can be applied for known 
or new (de novo) motifs. We used HOMER (Hypergeometric Optimization of Motif EnRich-
ment) [Heinz et al., 2010] to detect both. In addition, AME (Analysis of Motif Enrichment) 
was used to obtain statistical results for known motif variants of relevant transcription factors 
[McLeay et al., 2010]. De novo motif analysis revealed motifs similar to TBX5 motifs, but also 
of motifs similar to known co-factors of TBX5, such as MEF2, NKX2.5 and GATA4 (Figure 23, 
see section (5.2.4 for background information). Startlingly, the highest significance had a de 




















































































































































































































Similar to motif of:
MEIS1/2/3, NF1-halfsite, TGIF1/2
MEF2A/B/C/D





















De-novo motifs found enriched in the TBX5-ChIP-Seq show motif similarity to transcription fac-
tors of the MEIS, MEF, TBX, NKX and GATA family. 10 most significant de-novo motifs using HOMER [Heinz 
et al., 2010], transcription factor similarity shown for all annotated mammalian transcription factors.
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Secondly, TBX5 presence influenced MEIS1 binding patterns. Three effects could be distin-
guished: On a first group of targets the binding of MEIS1 was diminished in the vTbx5KO 
hearts (Figure 24C - Scn5a, Chrm2) indicating a dependance on TBX5 presence. The second 
group of targets showed enhanced binding in the absence of TBX5 (Figure 24C - Gja1, 
Gpr22) pointing towards a competitive action of both factors. The third group did not display 
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WT
KO
Chromatin occupancy by MEIS1 and TBX5 A. MEIS1 binding is enriched on TBX5 peaks. MEIS1 
ChIP-Seq from E11.5 embryonic trunks [Penkov et al., 2013] B. Peaks from the intersect of MEIS1 and TBX5 
bound regions are annotated with cardiac morphogenesis and heart contraction. C. ChIP-qPCRs in WT 
and KO hearts showed that TBX5 binding is diminished in the KO hearts. MEIS binding patterns change in 
the absence of TBX5. Experiments were performed by Lavanya Iyer Statistics: C. Unpaired students t-test 
was used to compare the enrichment in the KO hearts with the WT control hearts individually for each 
factor. p-value-summary: * - <0.05
8.6. Re-expression of TBX5
We established that TBX5 KO leads to conduction disturbances and diastolic dysfunction and 
this is mediated by the transcriptional dysregulation of several transcripts and their encoded 
proteins. Next, we tested if the reintroduction of TBX5 in the heart can lead to a reversal of 





































AAV6-in vitro validation in neonatal rat cardiomyocytes A. The coding sequences for TBX5/
CX43/GIRK4 were flag-tagged and introduced into the pds-TnnT vector under the control of a TnnT pro-
moter. B. Neonatal rat cardiomyocytes were transduced with adeno-associated virus serotype 6 at a mul-
tiplicity of infection of 100.000. Expression analyses by immunoblot showed a successful transduction C. 
TBX5-flag is localized in the nucleus of the NRCMs; CX43 appears mainly at connections between the 
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In vivo re-expression of TBX5 restores TBX5 mediated transcription A. The transcript levels of 
newly identified ventricular TBX5 targets are significantly enhanced by TBX5 re-expression (KO-RE, blue) 
as compared to control groups (KO-CT, red). The only target that was not significantly induced was Sc-
n5a. B. CX43 and FHL2 protein levels are increased by TBX5 re-expression determined by immunoblot with 
densitometric quantification C. Representative immunofluorescence picture detected CX43 at the interca-
lated disks of KO-RE ventricles similar to Cre controls. In contrast, KO-CT ventricles show almost no CX43 
expression. Statistics: A, one-way-ANOVA for each transcript; B, Student’s-t-test. * p < 0.05 vs. KO-CT.
To reintroduce TBX5 and its target genes into the hearts of vTbx5KO mice, we used ade-
no-associated virus (AAV) (5.6 for details). The coding DNA sequence of murine TBX5, CX43 
and GIRK4 was tagged with a flag-tag and cloned into the pds-TnnT vector, which allows 
cardiomyocyte-specific expression (Figure 25A). This vector can be used to generate AAV6 
for in vitro and AAV9 for in vivo transduction with a cardiac tropism. 
8.6.1. In vitro validation
To test the expression prior to in vivo experiments, AAV6 were generated to infect neonatal 
rat cardiomyocytes in vitro. Protein expression of TBX5, CX43 and GIRK4 could be detected 
by immunoblot (Figure 25B). The correct intracellular localization was confirmed by immu-
nofluorescence (Figure 25C). TBX5 localized in the nucleus whereas CX43 localized at cell-
to-cell junctions and GIRK4 localized at the cell surface/perinuclear.





























AAV9-mediated TBX5 delivery leads to cardiac specific re-expression of TBX5 A. Immunoblot 
analysis directed against TBX5 revealed a specific re-expression in the heart upon AAV9-TBX5 delivery 
(KO-RE) compared to AAV9-LUC (KO-CT). Band I represents the flagged-tagged TBX5, band III the endog-
enous TBX5, Band II is unspecific staining. B. AAV9-CX43 (KO-CX) did not lead to a detectable CX43 ex-
pression, but AAV9-TBX5 did. C. In the KO-RE hearts, TBX5 is expressed in the nuclei of cardiomyocytes 
(white arrowheads). Scale bar: 20 µm Immunostaining performed by Yelena Sargsyan.
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After verifying that the molecular signature is reversed after re-expression of TBX5, we per-
formed echocardiography analysis over a time course of 16 weeks after recombination. None 
of the measured parameters showed any statistical differences between the KO group re-
ceiving the control AAV and the KO group receiving AAV9-TBX5 (Figure 28) due to the low 
number of mice. Although not statistically significant, the KO-CT mice showed a tendency 
of progressive deterioration of cardiac function at 12 - 16 weeks measured by FAS and EF 
(Figure 28B and C). The contractile function of the KO-RE mice remained stable over time. 
As a consequence of normalized target gene expression, a rescue of the arrhythmic pheno-
type seen in the TBX5-KO mice (8.2.2 for details) would be expected. Thus, we examined 
the cardiac rhythmicity of Cre control, KO-CT and KO-RE hearts over 1000 consecutive beats 
using Poincaré RR-plots and calculation of  the standard deviation 1 (SD1). Indeed, KO-RE 
mice show a more regular beating pattern than KO-CT mice, represented by a smaller SD1(-
Figure 29A-C). Moreover, TBX5 re-expression was able to reduce the prolongation of the 
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In vivo TBX5 re-expression rescues arrhythmic phenotype of vTbx5KO mice A. Heart-rate-varia-
bility (HRV) represented by Poincaré plots is lower in KO-RE indicative of less AV blocks than KO-CT. 1000 
consecutive beats per mouse/plot. B, The Poincaré plots were statistically analysed with HRVAS [Ramshur, 
2010]. Standard deviation of the HRV (SD1) increased in KO-CT mice with time, while remaining stable 
in KO-RE mice. Dashed lines indicated Cre-average values ± SEM. C. Statistical analysis of SD1 from HRV 
analysis, shows significantly lower HRV in KO-RE vs. KO-CT mice. D. QRS prolongation in the KO-RE mice is 
partially reversed after TBX5 re-expression. Statistics: C+D: Student’s-t-test. * p < 0.05 vs. KO-CT.
Although the low number of mice did not allow a thorough survival study, it is important to 
note, that all KO-RE mice (n=5) survived at least 170 days after recombination, whereas 2 out 
of 6 KO-CT mice died during that time span. 
In summary, larger studies including more animals are needed to prove if the TBX5 normali-
zation can improve contractile function and survival. But this study could already show that 
TBX5 normalization can restore target gene expression and rescue the arrhythmic phenotype. 
After in vitro validation of the AAV6 constructs, we used AAV9 to re-express TBX5 in vivo, 
after inducing TBX5 KO. TBX5 protein was found to be expressed in the heart, but not in the 
liver or spleen (Figure 26A) of re-expression mice (KO-RE). AAV9-TBX5 delivery could induce 
expression of CX43, but AAV9-CX43 could not (Figure 26B). Moreover, TBX5 was localized 
in the nuclei of cardiomyocytes in the KO-RE mice (Figure 26C).
As a consequence of the TBX5 re-expression in the cardiomyocyte nuclei, we expected re-ex-
pression of its target genes. Quantitative qPCR for mRNA expression showed a robust re-ex-
pression of Tbx5 itself along with its targets Gja1, Kcnj5, Kcng2, Cacna1g, Chrm2, Fhl2, 
Gpr22 and Fgf16 (Figure 27A) comparable with Cre controls. 
Exemplary, we confirmed the expression of the targets CX43 and FHL2 by immunoblot, 
showing a similar re-expression on protein level (Figure 27B). In the KO-RE hearts CX43 was 
distributed homogeneously throughout the myocardium and correctly located within the 





























































In vivo TBX5 re-expression has no significant effect on functional parameters measured by 
echocardiography No statistical differences could be observed between KO-CT and KO-RE groups, nei-
ther for HW/BW ratio (A), FAS (B), EF (C) or CO (D) Statistics: Two-Way ANOVA (repeated measures)
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tal stage used an undefined mixed background [Sereti et al., 2018] and the vTbx5KO mice 
were maintained in a C57BL/6N strain. 
These data suggest that atrial recombination efficiency might be due to reduced Cre expres-
sion in the atria depending on the development stage and further influenced by differences 
in the genetic background of the mice that greatly varied among studies.
Although we cannot fully explain the molecular background of this compartment specific 
recombination, it provides us with a model to specifically study the role of TBX5 in the adult 
working myocardium.
9.1.2. Reduced heart growth and diastolic dysfunction
To study the functional consequences of the ventricular loss of TBX5 we performed a time 
series of echocardiographic examinations. This revealed that the vTbx5KO mice had no phys-
iological heart growth after recombination and cardiac function deteriorated over time in-
dicated by a decrease of ejection fraction and diastolic volume (8.2.1 for details). These 
observations show a more severe phenotype compared to a heterozygous constitutive KO 
model. This model was observed with reduced ventricular diameter and prolonged relaxa-
tion, but no changes in contractile function [Zhou et al., 2005] in contrast to the vTbx5KO. 
Because these heterozygous mice had mostly presented cardiac structural abnormalities, 
another study investigated the cardiac function in mice with a haploinsufficient KO of TBX5 
under the control of Nkx2.5-Cre. These mice did not have atrial or septal defects, but still suf-
fered from diastolic dysfunction, indicated by lower E/A ratio as well [Zhu et al., 2008]. Both 
studies using haploinsufficient mice did not find problems in systolic function and fractional 
shortening was unchanged. Our study confirmed the previously shown diastolic dysfunction 
and reduced end-diastolic ventricular dimension, but also found a reduced ejection fraction. 
This can be explained by the homozygous loss of TBX5 from the ventricles, but also by the 
extended time period in our study (16 weeks after KO - 28-30 weeks of age; whereas the 
other studies used 8-10 week old mice). Both circumstances might lead to the development 
of a more severe phenotype. 
9.1.3. Conduction defects, arrhythmia and sudden cardiac death
Because of the known association of TBX5 with cardiac rhythm and arrhythmias observed 
during echocardiographic analysis, we examined the cardiac rhythm of the vTbx5KO mice 
by telemetric electrocardiography. The vTbx5KO mice presented conduction defects and ar-
rhythmia, most prominently slower signal propagation (8.2.2). 
Similar conduction problems also occur in constitutive globally haploinsufficient KO models 
with a varying range of TBX5 expression levels summarized by [Mori et al., 2006], mainly 
describing prolonged PQ-intervals, third degree AV-Block, sinoatrial pauses and tachycardia.
Inducible removal of TBX5 from the cardiac conduction system (CCS) leads to conduction 
problems and SCD, but only ~25% of the mice die up until 300 days after recombination 
[Arnolds et al., 2012]. In our model, 60% of the mice died until 150 days after recombination 
9. Discussion
The major global health burden of cardiac disease requires new therapies. Interestingly the 
transcription factor TBX5, which was mainly investigated in the context of development, has 
recently been found dysregulated in cardiac disease [Baurand Anthony et al., 2007], [Horton 
et al., 2016] (own unpublished data) (5.5.2 for details). Therefore, we hypothesized that 
TBX5 could be required for homoeostasis of the working myocardium and its dysregulated 
expression in cardiomyopathies contributes to a deterioration of cardiac function. In order to 
proof this, we investigated the phenotypical and molecular consequences using an inducible 
cardiac specific TBX5 KO mouse model.
9.1. Basic Phenotype of the vTbx5KO mice
9.1.1. Ventricular specific recombination
The aforementioned model was generated by mating the TBX5LDN/LDN model (harbouring loxP 
sites flanking Exon 3 of the Tbx5 gene) with the Myh6-MerCreMer mouse strain, in which 
the expression of the tamoxifen-inducible Cre recombinase is controlled by the Myh6-pro-
moter. This promoter is supposedly active in all types of cardiomyocytes [Lyons et al., 1990] 
and thus the MerCreMer should be expressed in the whole heart. Indeed, we found Cre ex-
pression in the nuclei of atrial and ventricular tissue (7.1.1 for details). A number of publica-
tions, including the first description of the Myh6-MerCreMer mouse strain [Sohal Dawinder 
S. et al., 2001] show recombination throughout the whole heart. But to our surprise, robust 
TBX5 recombination did not occur in atrial cardiomyocytes, but was restricted to the ven-
tricles. Inefficient atrial recombination in adult Myh6-MerCreMer mice has been described 
previously [Shen et al., 2011] [Hsieh et al., 2007]. 
Interestingly, in embryonic and early postnatal stages high atrial recombination efficiency 
was described, but the same study showed low efficiency in the atria at postnatal day 12 
[Sereti et al., 2018]. The same decreasing atrial recombination efficiency was observed, when 
MerCreMer was inserted after the endogenous Myh6-promoter into the locus [Yan et al., 
2015] and even the original publication showed stronger atrial recombination at the age of 
17 days compared to three months old mice [Sohal Dawinder S. et al., 2001]. In line with 
these observations, a recent publication showed much lower reporter gene expression under 
the control of a Myh6-promoter in atria compared to ventricles in 6 week old mice [Carroll 
et al., 2016]. 
Another factor influencing the recombination efficiency could be the genetic background of 
the mice. The original characterization of the Myh6-MerCreMer mouse was performed in the 
FVB mouse strain and showed atrial recombination [Sohal Dawinder S. et al., 2001]. After the 
initial characterization these mice were backcrossed into a background of C57BL/6SV129. 
These mice were mated with ZEG mice and C57BL/6J mice to generate a transgenic model 
which showed no atrial recombination [Hsieh et al., 2007]. The other study demonstrating 
inefficient atrial recombination used a mixed 129 / black swiss background [Shen et al., 
2011], the study showing differences in atrial recombination depending on the developmen-
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from immature cells like differentiated cardiomyocytes [Luna-Zurita et al., 2016] or embryon-
ic heart [Steimle et al., 2018], we decided on an adult ventricular specific analysis, since the 
targets of TBX5 in the adult heart might be different from early developmental stages 
The sequencing of this TBX5-bound chromatin showed the TBX5 genomic occupancy in the 
adult heart. In line with previous studies (5.2.4 for details) proving the interaction of TBX5 
with NKX2.5 and GATA4, we found a correlation between the binding regions of those 
transcription factors as well as an enrichment of their corresponding motifs in the TBX5 
peaks. Not only did TBX5 occupancy overlap with other transcription factors, but also with 
marks of active enhancers. Accordingly, the TBX5-bound regions marked by active enhancers 
showed a greater overlap with the genes downregulated (47 of 97) in the vTbx5KO hearts 
compared to the upregulated genes (7 out of 93) detected by transcriptomic analysis. This 
points towards a rather transcriptionally activating role of TBX5 in the adult heart. Indeed, 
the transcriptionally repressive role of TBX5 has so far been established in the developmental 
stage only [Waldron et al., 2016].
9.3. TBX5 targets
The aforementioned novel targets of TBX5 include transcripts important for cardiac con-
duction, cardioprotection and cardiomyocyte structure. These affected transcripts might be 
crucial to understand the phenotype of the vTbx5KO mice, since they show conduction 
defects, exacerbated hypertrophic response upon stress [Renger, 2012] and problems with 
cardiomyocyte growth.
9.3.1. TBX5 targets implicated in cardiac conduction
9.3.1.1. Gja1
One of the identified targets with a severely reduced expression in the vTbx5KO was Gja1 
(encoding for CX43), the dominant gap junction protein in the adult ventricle (5.3.1.2 for 
details). This severely reduced expression can explain the significantly slower ventricular con-
duction and incidence of SCD, since loss of CX43 leads to arrhythmias and SCD as well 
[Gutstein et al., 2001]. 
Since [Nadadur et al., 2016] already identified Gja1 as a target of TBX5 in the atria, they looked 
for a specific enhancer and investigated this putative enhancer (mm9 chr10:88816980–
88817471). Activation of this candidate enhancer by TBX5 was confirmed, although no 
direct link of this enhancer to Gja1 expression was established. We could not detect binding 
of TBX5 to this enhancer in TBX5-ChIP-Seq neither in adult ventricular myocardium nor in 
the embryonic [Steimle et al., 2018] nor in differentiated cardiomyocytes [Luna-Zurita et al., 
2016]. However, the binding might be tissue-specific. Instead, the enhancer we identified 
as a candidate enhancer for Gja1 in the ventricular myocardium is significantly closer to the 
gene body (although still 600 kb away) in contrast to 32 mb and consistent over all published 
TBX5-datasets. Moreover, this enhancer has been found to drive embryonic expression spe-
cifically in the heart (data from Vista enhancer browser [Visel et al., 2007], ID mm74). These 
was induced. Nevertheless, QRS- and PR-interval duration in both models were comparable 
(QRS CCS-KO: 15.3 ± 2.6; vTbx5KO: 17.6 ± 1.9; PR CCS-KO: 51.8 ± 1.2; vTbx5KO: 48.3 ± 
4.5). This indicates, that TBX5 plays an important role for cardiomyocyte homoeostasis be-
yond the conduction system. 
A study focusing on the effects of TBX5-loss in the atria used an inducible global TBX5-KO 
model [Nadadur et al., 2016]. This led to irregular heart rate and atrial fibrillation. The au-
thors observed ventricular arrhythmias happening at later time points than atrial arrhythmias 
and thus claimed, that they are only a secondary effect of the atrial arrhythmias [Nadadur et 
al., 2016]. However, after observing several ventricular arrhythmias in the absence of atrial 
recombination and atrial fibrillation, we hypothesised, the ventricular arrhythmias, although 
less prominent, are a direct effect of ventricular TBX5-loss.
Besides the PR- and QRS-prolongation, we found a prolongation of the QT-interval in the 
vTbx5KO hearts, which would be indicating a prolonged repolarisation phase in the human 
ECG. However, the action potential duration measured in isolated vTbx5KO hearts was un-
changed. Indeed, in mice the measurement of the QT-interval is problematic due to the fast 
cardiac cycle in the murine heart [Zhang et al., 2014]. QT-prolongations can be a conse-
quence of a longer QRS-complex, therefore a sign of slower signal propagation occurring in 
the vTbx5KO model.
9.2. Integrative Target Gene Analysis
After we found that a homozygous loss of TBX5 in the adult ventricle leads to reduced heart 
growth, diastolic dysfunction, arrhythmia and sudden cardiac death, we intended to inves-
tigate the underlying molecular mechanism. Therefore, we aimed to uncover the chromatin 
binding sites of TBX5 in the adult ventricle and to reveal the differentially regulated genes in 
vTbx5KO vs. control hearts. 
This RNA-Sequencing revealed upregulated genes, that were not directly linked to the con-
tractile and conduction defects of the vTbx5KO mice, but were instead related with blood 
coagulation. Since TBX5 is neither known to be involved in blood coagulation nor to be 
expressed in thrombocytes, the appearance of this gene cluster can probably be attributed 
to blood clots observed in the atria of the vTbx5KO mice. These clots are possibly an adverse 
effect of abnormal blood flow caused by the arrhythmia and diastolic dysfunction. Diastol-
ic dysfunction is associated with bigger atrial volumes [Pritchett et al., 2005][Aouar et al., 
2013]. Along with the atrioventricular block observed in the vTbx5KO mice, this might lead 
to problems with the ejection of blood from atria to ventricles resulting in blood clotting. In 
contrast to the upregulated genes that were not clearly connected to the phenotype, the 
downregulated targets are directly implicated in heart contraction and electrophysiology.
In addition to the analysis of differentially regulated genes upon TBX5 loss, we established a 
protocol for chromatin immunoprecipitation of TBX5 from adult heart tissue to detect a di-
rect transcriptional regulation by TBX5. Although TBX5 ChIP-Seq results have been published 
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9.3.2. TBX5 target genes with a role in cardioprotection
Besides the genes implicated in cardiac electrophysiology, we identified targets known to 
protect the heart from cardiac stress:
9.3.2.1. Fhl2
Firstly, Fhl2 has been found to be downregulated upon TBX5 loss by us and others [Mori et 
al., 2006]. Fhl2 increases upon β-adrenergic stress induced by Isoproterenol [Hojayev et al., 
2012]. Moreover, Fhl2KO-hearts respond to this cardiac stress by increased hypertrophy, in-
dicated by higher HW/BW ratio and elevated ANP and BNP levels [Hojayev et al., 2012][Kong 
et al., 2001]. FHL2 in turn induces TBX5 expression by direct activation of the TBX5 promoter 
[Renger, 2012].
9.3.2.2. Gpr22 and Fgf16
Secondly, Gpr22 is an orphan G-protein coupled receptor mainly expressed in the heart and 
brain with reduced expression after TAC [Adams et al., 2008] and upon TBX5 loss. A global 
KO of Gpr22 leads to exacerbated cardiac function upon aortic banding [Adams et al., 2008].
Finally, we show that fibroblast growth factor 16 (Fgf16) expression is reduced upon TBX5 
loss. This is in agreement with previous studies, showing Fgf16 expression to be activated by 
GATA4 [Yu et al., 2016].  FGF16 itself represses Nppa and Nppb and overexpression of FGF16 
protects the hearts from cryoinjury [Yu et al., 2016].
9.3.2.3. Cardiac function of vTbx5KO mice upon cardiac stress
Due to these cardioprotective factors being expressed at reduced levels in the vTbx5KO mod-
el, it would be plausible, if those hearts show increased response to cardiac stress. Indeed, 
when vTbx5KO mice are treated with Angiotensin II, they respond with a decrease in ejection 
fraction (EF) and increase in hypertrophy [Renger, 2012]. Furthermore, hypertrophy occurs at 
a single cell cardiomyocyte level by an increase in cross-sectional area [Renger, 2012]. At the 
same time, the hearts react by developing fibrosis at a higher extent than the hearts of Flox 
mice [Renger, 2012].
We hypothesise that this phenotype can be explained by the dysregulation of Fhl2, Gpr22, 
Fgf16 and potentially Cacna1g and that those factors might be relevant for the diastolic dys-
function of the vTbx5KO model in general.
9.3.3. TBX5 target genes with other functions
To gain further insight into the role of TBX5 in cardiac homoeostasis we looked into novel 
target genes possibly important in cardiac remodelling.
9.3.3.1. Armh4
One of the most down-regulated transcripts in the TBX5 KO was Armh4 (armadillo-like hel-
ical domain containing 4). We verified, that it is downregulated on mRNA and protein level 
and identified two possible TBX5 binding sites in its promoter region. ARMH4 was found to 
be expressed in the z- and intercalated discs of cardiomyocytes (8.4.1 for details).
results strongly suggest that this enhancer downstream of the Gja1 gene body mediates 
TBX5-initiated expression.
9.3.1.2. Kcnj5
Along with Gja1, Kcnj5 was suggested as a TBX5 target gene in the atria as well, because 
of its reduced expression upon TBX5 loss [Nadadur et al., 2016]. Indeed, we found reduced 
Kcnj5 expression in the ventricles of vTbx5KO mice as well. Moreover, we showed transcrip-
tional activation by TBX5 on an enhancer located less than 1 kb downstream of the Kcnj5 
gene (8.6.1 for details).
Kcnj5 is expressed in atria and ventricles. Although it contributes to repolarisation in both 
compartments, its expression and its functional relevance seem to be higher in the ventricle 
[Liang et al., 2014] [Anderson et al., 2018]. Kcnj5 KO mice show no difference in their basal 
heart rate, but react differently to parasympathetic stimuli [Wickman et al., 1998] [Anderson 
et al., 2018]. Consistent with that, vTbx5KO mice do not show differences in their basal 
heart rate. KCNJ5 is associated with long-QT syndrome in humans and long-QT syndrome is 
a risk factor for SCD [Yang et al., 2010]. The vTbx5KO mice showed longer QT-intervals as 
well, but since in mice this is not always indicative of a prolonged repolarisation phase (9.1.3 
for details), it requires further investigation if aberrant Kcnj5 expression is contributing to the 
SCD phenotype observed in our study.
9.3.1.3. Kcng2, Cacna1g and Chrm2
Three other genes dysregulated in the vTbx5KO model, bound by TBX5 and related to elec-
trophysiology are Kcng2, Cacna1g and Chrm2.
Kcng2 encodes for potassium voltage-gated channel, subfamiliy G, member 2 and is dys-
regulated upon TBX5 loss in the atria as well [Nadadur et al., 2016]. This protein is a subunit 
of a propafenone-sensitive potassium-channel expressed in the heart [Zhu et al., 1999]. It is 
not known, how it is regulated and how relevant it is for cardiomyocyte electrophysiology.
Cacna1g encodes for calcium channel, voltage-dependent, T-type, alpha 1G subunit, a sub-
unit of a T-type calcium channel on the surface of cardiomyocytes. A KO of Cacna1g leads 
to adverse cardiac remodelling upon cardiac stress, with more hypertrophy and disturbed 
electrophysiology [Le Quang Khai et al., 2013], reviewed by [Fabritz et al., 2011].
Polymorphisms in the cholinergic receptor, muscarinic 2, cardiac (CHRM2) gene are signif-
icantly associated with the heart rate adjustment and cardiac death [Hautala et al., 2009]. 
Patients with a missense mutation in CHRM2 present with dilated cardiomyopathy, suffer 
from arrhythmia and are at higher risk for sudden cardiac death [Zhang Lin et al., 2008].
Because a number of transcripts with a role in cardiac electrical signal propagation show a re-
duced expression in the vTbx5KO model, the slower signal propagation of the hearts can be 
explained. We hypothesise, that Gja1 plays the main role in the slower signal propagation, 
but disturbed expression of Kcnj5, Kcng2, Cacna1g and Chrm2 is likely to further increase 
the risk for arrhythmia and sudden cardiac death.
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There is no information on the function of Pdlim4 in the heart, but it might play a role in 
cytoskeleton organisation.
Although a possible implication of Armh4, Cmya5, Emilin2 and Pdlim4 in cardiac remodelling 
requires more in depth studies of their function, observations indicate that these proteins are 
expressed in cardiomyocytes and show aberrant expression in the context of disease or are 
even directly linked to a cardiomyopathy phenotype. The dysregulation of these factors in 
the vTbx5KO hearts probably contributes to a worsening of the phenotype.
9.4. Chromatin Occupancy of TBX5
As no chromatin occupancy studies of TBX5 have been performed in adult hearts, we were 
interested to compare our model to existing studies examining chromatin binding properties 
of TBX5 in mouse, using embryonic hearts from E9.5 [Steimle et al., 2018], in vitro differen-
tiated cardiac progenitor cells / cardiomyocytes [Luna-Zurita et al., 2016] or overexpressed 
tagged-TBX5 protein in the HL-1 cell line [He et al., 2011]. Specifically, we were interested to 
examine differences and similarities between these and our dataset. This could allow insights 
into stage-specific functions of TBX5.
In the adult heart TBX5 shows enriched binding to promoter, 5’UTR, intronic and down-
stream of the gene body regions compared to the genome background (8.3.1 for details). 
This is comparable to  the data from E9.5 hearts [Steimle et al., 2018] and HL1-cells [He et al., 
2011], both showing enrichment of promoter and downstream peaks (Table 37). However, 
TBX5 promoter binding was less in differentiated cardiac progenitor cells and cardiomyocytes 
[Luna-Zurita et al., 2016]. This might be confounded by differences in the methods, since 
these differentiated cells were subjected to ChIP-Exo resulting in narrower peaks. 
Although the datasets obtained from heart tissue show overlapping peaks on regions active 
both in the embryonic and adult state, they have distinct binding patterns. A high number of 
regions is highly conserved for all published TBX5 datasets [Steimle et al., 2018], [He et al., 
2011], [Luna-Zurita et al., 2016] like the Scn5a, Gja5, Gja1, Kcnj5, Cacna1g, Fhl2 and Cmya5 
enhancer. Other regions are exclusively bound in the embryonic (e.g. Wnt2, Fgf10, Rictor) 
or in the adult stages (Fgf16, other Scn5a enhancers). Interestingly, in the immature stages 
TBX5 shows higher affinity to regions related to differentiation and development, whereas 
in the adult stages the affinity to regions related with cardiac homoeostasis and electrophys-
iology is higher (Table 37).
This allows the conclusion that factors implicated in cardiac electrophysiology are regulated 
by TBX5 independent of the developmental stage, although they are partially bound on 
different enhancers. In the immature stages enhancers involved in muscle development and 
cardiac morphogenesis require activation by TBX5. In contrast, the adult heart requires a 
stronger emphasis on cardioprotective factors indicated by stronger binding of Fhl2, Fgf16 
or Emilin2.
Armh4 was initially identified during mESC differentiation to cardiomyocytes [Christoforou 
et al., 2008]. In situ hybridization verified transcript expression rising in embryonic heart 
at E7.5 [Christoforou et al., 2008]. Public data (EUREXPRESS DATABASE) show that in the 
mouse embryo the transcript expression of Armh4 and Tbx5 strongly correlate at dorsal root 
ganglia, retina, and regions of the brain suggesting a link between the two proteins that is 
not only restricted to the heart.
Interestingly, the human homologue of ARMH4 is predicted to be a glycosylated single pass 
membrane protein type I (similar to beta subunits of sodium channels, integrins and cadher-
ins) (Uniprot) [Huttlin et al., 2017]. In human leukaemia cells ARMH4 (in this context named 
upstream of mTORC2 (UT2)) inhibits RICTOR, a component of the mTORC2 signalling com-
plex [Lee et al., 2014]. Additionally, ARMH4 interacts with GP130 to inhibit phosphorylation 
of STAT3, thereby reducing cytokine signalling in hematopoetic malignancies [Lee et al., 
2016]. Both studies detected UT2 to act as a tumorsuppressor, resulting in reduced prolifer-
ation and prolonged survival.
A conditional cardiomyocyte-specific Rictor KO mouse model simulates mTORC2 up-reg-
ulation [Shende et al., 2016]. These mice have normal survival and cardiac function on a 
basal level, but upon cardiac stress by transaortic constriction (TAC) they show dilation and 
reduced ejection fraction and fractional area shortening already one week after TAC, when 
control mice are only in the compensatory phase of hypertrophy [Shende et al., 2016].
The function of ARMH4 in the heart remains unknown so far, but if it interferes with mTORC2 
signalling in the heart in a similar manner like in leukaemia cells, its KO might be protective 
upon cardiac stress.
9.3.3.2. Cmya5
Cmya5 (Cardiomyopathy associated 5) encodes for the Myospryn protein and its expression 
is regulated by MEF2A [Durham et al., 2006]. Cmya5 expression is altered after aortic band-
ing [Knyazeva et al., 2019] and an association between a polymorphism in the CMYA5 gene 
(rs2278239) and cardiac disease has been found [Nakagami et al., 2007]. Myospryn interacts 
with ryanodine receptors and plays a role in their assembly in the sarcoplasmic reticulum 
[Benson et al., 2017].
9.3.3.3. Emilin2
Emilin2 (Elastin microfibril interface located protein 2) has been identified as a protein on the 
cardiomyocyte cell surface [Van Hoof et al., 2010]. A loss of Emilin2 leads to congenital car-
diac anomalies, like ventricular septal defects, atrioventricular canal defects and hypoplastic 
ventricles potentially through interference with the TGF-β1 pathway [Guggilam et al., 2016]. 
Emilin2 expression is upregulated upon isoproterenol induced hypertrophy [Molojavyi et al., 
2010].
9.3.3.4. Pdlim4
Pdlim4 (PDZ and LIM domain 4) directly interacts with F-actin [Vanaja et al., 2009]. It is ex-
pressed in the heart at higher levels than in skeletal muscle [Komurcu-Bayrak et al., 2012]. 
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9.5. Biological interaction between MEIS1 and TBX5
Because de novo motif analysis of the adult TBX5 ChIP-Seq data showed a strong enrich-
ment of a motif similar to MEIS1/2 motifs, we became interested in looking into a possible 
relationship between the two transcription factors. The MEIS1 motif core (TGACAG) had 
been found previously in ChIP-Exo against TBX5 in cardiac progenitor cells and cardiomyo-
cytes  [Luna-Zurita et al., 2016]. The authors suggested, this finding could be attributed to 
its close similarity to the 3’end of alternate motifs of TBX3/5 and 20. But interestingly, a SNP 
in the MEIS1 gene is associated with prolonged PR-intervals, as are SNPs in TBX5, its co-fac-
tor NKX2-5 and its target SCN5A [Pfeufer et al., 2010] [Smith et al., 2011]. TBX5 and MEIS 
transcription factors are both involved in limb development. TBX5 is required for patterning 
of the forelimb identity [Rodriguez-Esteban et al., 1999] [Bruneau et al., 2001], whereas 
MEIS1/2 are involved in the proximal-distal organization of the limbs [Mercader et al., 1999] 
[Capdevila et al., 1999]. Moreover, MEIS1 and NKX2-5 as a known co-transcription factor of 
TBX5 bind mutually exclusive to overlapping motifs [Dupays et al., 2015]. In murine hearts 
with a KO of Meis1, Tbx5 was found to be twofold upregulated [Mahmoud et al., 2013], 
possibly a compensatory mechanism. Finally a KO of Meis1 in the peripheral nervous system 
can lead to conduction defects and sudden cardiac death [Bouilloux et al., 2016] similar to 
Tbx5 loss. These data pinpoint towards a biological relevance of the appearance of a MEIS 
motif in the TBX5-ChIP-Seq dataset instead of a coincidence of motif similarity. 
Therefore, we investigated a potential interaction between MEIS1 and TBX5. In silico analysis 
showed an enrichment of MEIS1 binding in a ChIP-Seq from embryonic trunks [Penkov et al., 
2013] on TBX5 bound regions. These common regions are related to cardiac morphogenesis 
and muscle function, indicating a possible biologically relevant relationship between both 
transcription factors. Moreover, ChIP of MEIS1 and TBX5 in the heart showed enrichment of 
both transcription factors on the enhancers of Scn5a, Kcnj5, Cacna1g and Chrm2. Interest-
ingly, MEIS1 was able to bind the enhancers of Gja1 and Gpr22 stronger in the absence of 
TBX5, but lost the ability to bind the Scn5a and the Chrm2 enhancer, when TBX5 was not 
present.
These data indicate a biological interaction between TBX5 and MEIS1, since both bind to the 
same enhancer regions. However, further investigations need to identify whether the two 
factors act in a competing or synergistic fashion.
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able to induce significant expression of TBX5. For CX43 higher expression levels might be 
necessary to induce a significant change to the endogenous expression of CX43. This could 
be achieved by using for example a CMV-promoter associated with a higher risk of unspe-
cific expression in other tissues. However, it might also be a technical issue, since the in vitro 
transduction of NRCMs with AAV6-CX43 lead to a markable induction of CX43 expression. 
A common issue in the production of AAVs is the contamination with empty capsids. These 
are not only reducing the number of particles able to transduce cells, but are also inhibiting 
the transduction efficiency of the fully packed particles [Gao et al., 2014]. Therefore, the 
batch of the AAV9-CX43 might not have been able to induce significant elevation of CX43 
expression.
However, we think, that the specific expression of TBX5 is a more relevant therapeutic target, 
because it can induce the induction of several targets to physiological levels without unspe-
cifically interfering with other organs.
9.6.3. Restoration of TBX5-target gene expression and rescue of the phenotype
Re-expression of TBX5 lead to an increase of all previously validated transcripts. The expres-
sion of the conduction related genes Gja1, Kcnj5, Kcng2,Cacna1g and Chrm2 was normal-
ized to levels similar to Cre control mice. CX43 protein expression was distributed in the 
ventricle comparable to Cre controls as well. The restoration of those target genes allowed a 
reversal of the QRS-prolongation and lead to a reduction of arrhythmia incidence. 
Besides conduction, also cardioprotective genes like Fhl2, Gpr22 and Fgf16 were re-ex-
pressed. Although not reaching statistical significance due to a low number of animals ex-
amined, the KO animals transduced with a control virus showed a progressive deterioration 
of their contractile function, whereas the TBX5-normalized hearts remained stable. Further 
experiments inducing cardiac stress in the TBX5-normalized animals could reveal, if they are 
protected better against pathological hypertrophy.
The Tbx5 re-expression only induced a weak and non-significant increase in Scn5a (8.6.2). 
Scn5a and Tbx5 are expressed at higher levels in the conduction system than in the working 
myocardium [Arnolds et al., 2012]. Although TBX5 re-expression seemed to lead to a physio-
logical expression level in the working myocardium, it might not reach its original expression 
levels in the conduction system, thus not being able to induce complete recovery of Scn5a 
expression.
Nevertheless, the re-expression of TBX5 led to a substantial rescue of the arrhythmic phe-
notype. KO-RE mice displayed lower heart-rate variability and less QRS-prolongation than 
KO-CT mice. Notably, there seemed to be a lower incidence of death in the TBX5-normalized 
mice.
A more extensive study would be able to answer the question if this rescue of the phenotype 
can indeed lead to a protection from sudden cardiac death. Furthermore, TBX5 re-expression 
in a cardiomyopathy model, that is not attributed to direct TBX5-loss, is of high importance 
for potential translational implications.
9.6. Re-expression of TBX5
TBX5 is expressed at reduced levels in cardiac disease both in rodents [Baurand Anthony 
et al., 2007] [Horton et al., 2016] and humans (5.5 for details). This study showed, that a 
ventricular loss of TBX5 disrupts the transcriptional homoeostasis leading to heart failure, 
arrhythmia and sudden cardiac death. Hence, we hypothesized that a normalization of TBX5 
expression could restore transcription of its target genes and ameliorate the phenotypic con-
sequences of TBX5 loss. To test this hypothesis, we selected an adeno-associated viral (AAV) 
approach.
9.6.1. AAVs as a research tool and in a preclinical therapeutic concept
Lately, AAV became of interest as a research tool, since it allows testing of overexpression of 
a protein of interest as an alternative or combined approach to generating transgenic animal 
models. An example of this approach was a study overexpressing of Rbm24 via AAV9 under 
the control of a CMV-promoter. This way it could be established that Rbm24 led to fibrosis 
induction [Hoogenhof et al., 2018]. 
AAVs are not only used as a research tool, but also for therapeutic proof-of-concept studies 
in small animal models. One study presented the cardio-selective overexpression of junc-
tophilin-2 under the control of a myosin-light-chain promoter. This AAV9-application was 
able to rescue the contractile dysfunction in mice after TAC [Reynolds et al., 2016]. Another 
publication selected a comparable approach to our study: They injected constitutive De-
smin-KO mice with AAV9 encoding desmin with a TNNT2-promoter and were able to show 
an amelioration of cardiac function providing proof-of-principle for a potential gene therapy 
for desmin-related cardiac disease [Heckmann et al., 2016].
Based on this study we selected the serotype AAV9 and the TnnT2-promoter to drive TBX5 
(or CX43) expression. The aim was to determine the therapeutic effect of TBX5 re-expres-
sion, but also to examine the effect of CX43 re-expression in the vTbx5KO model thereby de-
termining the contribution of CX43-loss to arrhythmia development. The viral particles were 
applied two weeks after induction of the vTbx5KO, since at this timepoint the transcription 
of target genes is disrupted and conduction delays can be observed.
9.6.2. Tissue-specific re-expression of TBX5
TBX5 was re-expressed in a tissue-specific manner in mouse hearts after KO of TBX5 by the 
use of adeno-associated viruses. Indeed, this corroborates the finding, that AAV9 has the 
highest cardiac transduction efficiency compared to serotypes 1-8 [Zincarelli et al., 2008]. 
Even higher specificity was achieved by using the cardiomyocyte-specific Tnnt2 promoter 
described earlier [Heckmann et al., 2016]. The re-introduction of CX43 by injection of AAV9-
CX43 however, did not lead to markable expression of CX43. This could be because of the 
higher expression of CX43 in general. Although Gja1 expression is strongly diminished in vT-
bx5KO ventricles, it is still 25-fold higher than the corresponding expression of Tbx5 (mRNA 
expression normalised to Gapdh was 0.061 ±0.018 for Gja1 and 0.0025 ±0.0017 for Tbx5 
in left ventricles) [own unpublished data]. Considering that TBX5 as a transcription factor is 
only expressed at low levels, the specific - but comparably weak - promoter of Troponin T is 
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In summary, our study suggests the potential of TBX5 as a target for arrhythmia and heart 
failure with underlying transcriptional dysregulation.
9.8. Translational Outlook
Heart failure and sudden cardiac death are a major health burden worldwide. From 2000 to 
2016 only an improvement from 41% to 48% in the 5-year survival rate of heart failure pa-
tients could be achieved with current treatments [Taylor et al., 2019]. For patients with end-
stage heart failure, the only option is a heart transplant. However, the shortage of donor or-
gans and costs of ~170 000 € per patient [Schröder, Dieter, 2013] prohibit the standard use 
of this therapeutic option. Therefore, better therapies are needed by patients and physicians.
Recently, research has focused on transcriptionally reprogramming the diseased heart in 
order to halt disease progression or even reverse pathological remodelling. This could be 
achieved by  introducing transcription factors to restore the expression of beneficial target 
genes. Our study demonstrates how re-expression of cardiac transcription factor TBX5 was 
able to reduce the risk for arrhythmia and improve survival in a vTbx5KO model. Thus, we 
provide proof of principle for transcriptional reprogramming as a therapeutic strategy in 
heart failure. Further, more extensive studies need to show, if restoration of TBX5 expression 
in a heart failure model can protect mice from sudden cardiac death.
Our study is however limited by the use of a small rodent model. While providing distinct 
advantages such as short generation time and easy handling, these models are limited when 
it comes to the translation of findings into human physiology. Therefore, further studies us-
ing large animal models of heart failure or engineered human tissues are required in order 
to evaluate the therapeutic potential of TBX5 normalisation for the prevention of arrhyth-
mia and sudden cardiac death. Especially engineered human tissue models, such as the 
engineered human myocardium (EHM) model allow for the fast investigation of therapeutic 
strategies in human disease models. In EHM, heart failure can be mimicked by pharmacolog-
ical induction of adverse remodelling and hypertrophy [Tiburcy et al., 2017]. In this kind of 
heart failure model, TBX5 normalisation by AAV delivery would be expected to halt disease 
progression and reverse functional phenotypes.
Considering the potential clinical application of TBX5, routes for transcription factor delivery 
need to be investigated. In our study we used recombinant adeno-associated viruses as two 
therapies using rAAVs have been previously approved for clinical use [Wang et al., 2019]. 
When these investigations can be confirmed in a large animal model of heart failure, they 
could translate from bench-to-bedside and lead to an amelioration of clinical therapies. 
An alternative to direct transcription factor delivery could be small molecules enhancing 
TBX5-expression or activity. In this context, stem-cell derived cardiomyocytes [Sharma et al., 
2017] or EHM [Meyer et al., 2019] offer a fast and high-throughput platform for the screen-
ing of small molecule libraries targeting TBX5 to find suitable candidates for human therapy. 
The easier application routes and lower costs of a targeted small molecule would allow a 
wide clinical application of a TBX5 based therapy for heart failure patients.
9.6.4. Adeno-associated viruses in larger animal models
After performing a larger study in small animals, an investigation in larger animals would 
be required before a translational into a clinical context. Already AAV9 with a cardiomyo-
cyte-specific promoter have been successfully used in a pig model of ischemic heart failure, 
induced by temporary ischemia [Pleger et al., 2011]. The authors applied 1.5 x 1013 viral 
particles directly to the anterior cardiac vein to achieve higher concentrations in the heart. 
Indeed, they were able to achieve high protein expression specifically in the anterior wall, 
compared to much lower expression in the posterior wall and negligible liver expression [Ple-
ger et al., 2011].
Altogether, several studies proof the feasibility of AAV9 transduction in vivo in smaller and 
larger animals. Our investigation showed, that TBX5 is able to revert a phenotype caused by 
loss of TBX5 in the working myocardium, as it occurs in heart failure patients.
9.7. Summary 
TBX5 is an essential transcription factor in the heart. So far, studies focused mainly on its role 
in development and the cardiac conduction system. But besides these established functions 
TBX5 expression is reduced in cardiac disease models in rodents and in heart failure patients. 
Therefore, we hypothesised that TBX5 is required for homoeostasis of the working myocar-
dium and thus used a ventricular specific inducible TBX5 KO model to explore the function 
of TBX5 in the working myocardium. 
These KO mice exhibited higher incidence of sudden cardiac death. Their hearts show dimin-
ished heart growth during aging along with diastolic dysfunction. Furthermore, they have 
slower cardiac conduction and arrhythmias similar to known models of TBX5 loss, though 
the phenotype (e.g. the incidence of sudden cardiac death) is more severe due to a complete 
loss of TBX5 throughout the ventricle.
We provide for the first time a full profile of endogenous TBX5-chromatin binding in the 
adult working myocardium, which can be applied in other studies to get more insights on 
transcription factor interactions and epigenetics in the heart. The integration of these results 
with RNA-Seq data revealed a number of novel targets for TBX5 and new putative enhancers. 
We validated several targets with an emphasis on Gja1 and Kcnj5 and could show that TBX5 
directly activates enhancers in their gene proximity. 
Besides known cofactors, motifs annotating to MEIS transcription factors were enriched in 
the TBX5-ChIP-Seq data and we thus collected hints for a biological interaction between 
both transcription factors. More extensive studies are needed to determine the relationship 
of MEIS1 and TBX5 in the heart.
Furthermore, we provide first proof-of-concept for the therapeutic potential of TBX5 resto-
ration in the diseased heart. As a potential approach, we tested TBX5 re-expression by AAVs 
in vivo in vTbx5KO hearts. Indeed, this re-expression led to a reversal of TBX5 expression and 
subsequently to a rescue of target gene expression and the arrhythmic phenotype. 
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11.2. Dysregulated genes in vTbx5KO
Table 38. Downregulated genes with a log2-fold-change (L2FC) <-0.8 and p <0.05
external_gene_id description L2FC padj
Gpr22 G protein-coupled receptor 22 -2.98 6.57E-33
Ttll1 tubulin tyrosine ligase-like 1 -2.60 2.30E-39
Aldob aldolase B, fructose-bisphosphate -2.40 2.51E-29
Gja1 gap junction protein, alpha 1 -2.23 1.60E-29
3632451O06Rik RIKEN cDNA 3632451O06 gene -2.23 6.43E-33
Cenpf centromere protein F -2.05 2.11E-18
Fgf16 fibroblast growth factor 16 -1.91 1.68E-19
Dbh dopamine beta hydroxylase -1.79 9.76E-07
Scn5a sodium channel, voltage-gated, type V, alpha -1.78 3.05E-14
9330158H04Rik RIKEN cDNA 9330158H04 gene -1.77 5.60E-18
Fstl4 follistatin-like 4 -1.75 6.29E-08
Kcnj5 potassium inwardly-rectifying channel, subfamily 
J, member 5 
-1.73 2.72E-27
Gm16316 predicted gene 16316 -1.66 7.13E-05
Gm10801 predicted gene 10801 -1.51 3.78E-04
Lrrc4b leucine rich repeat containing 4B -1.44 6.12E-08
Pde11a phosphodiesterase 11A -1.41 3.60E-06
Gm14492 predicted gene 14492 -1.39 7.91E-07
B3galt2 UDP-Gal:betaGlcNAc beta 1,3-galactosyltrans-
ferase, polypeptide 2 
-1.38 1.32E-03
Junb Jun-B oncogene -1.36 7.13E-04
Gm10435 predicted gene 10435 -1.35 5.45E-05
Fhl2 four and a half LIM domains 2 -1.35 1.64E-11
Chrm2 cholinergic receptor, muscarinic 2, cardiac -1.33 1.04E-12
Emilin2 elastin microfibril interfacer 2 -1.32 5.82E-08
Plekhh1 pleckstrin homology domain containing, family H 
(with MyTH4 domain) member 1 
-1.31 8.03E-07
Pdlim4 PDZ and LIM domain 4 -1.31 5.69E-10
Gm12295 predicted gene 12295 -1.28 3.11E-06
Gm16534 predicted gene 16534 -1.27 2.07E-04
Kcng2 potassium voltage-gated channel, subfamily G, 
member 2 
-1.27 2.11E-19
Cyr61 cysteine rich protein 61 -1.23 2.11E-03
Polr1e polymerase (RNA) I polypeptide E -1.23 6.83E-10
Fitm1 fat storage-inducing transmembrane protein 1 -1.21 5.82E-08
114 115
Efnb3 ephrin B3 -1.19 2.03E-12
Sbk2 SH3-binding domain kinase family, member 2 -1.18 4.98E-03
Entpd5 ectonucleoside triphosphate diphosphohydrolase 
5 
-1.17 3.03E-29
Cntn5 contactin 5 -1.16 7.23E-04
Lgi3 leucine-rich repeat LGI family, member 3 -1.15 6.09E-05
Rbfox1 RNA binding protein, fox-1 homolog 1 -1.15 2.86E-15
Cacna1g calcium channel, voltage-dependent, T type, al-
pha 1G subunit 
-1.15 1.69E-03
Nppb natriuretic peptide type B -1.15 1.37E-02
Gm10800 predicted gene 10800 -1.15 1.87E-02
Abra actin-binding Rho activating protein -1.13 1.98E-04
Tbc1d10c TBC1 domain family, member 10c -1.12 8.35E-08
Fam81a family with sequence similarity 81, member A -1.11 7.57E-08
Adam11 a disintegrin and metallopeptidase domain 11 -1.11 7.36E-03
Ankrd63 ankyrin repeat domain 63 -1.09 2.90E-03
Slc17a7 solute carrier family 17 (sodium-dependent inor-
ganic phosphate cotransporter), member 7 
-1.08 5.05E-03
Gm26924 predicted gene, 26924 -1.06 2.26E-02
Egflam EGF-like, fibronectin type III and laminin G do-
mains 
-1.05 7.75E-12
Sh3kbp1 SH3-domain kinase binding protein 1 -1.04 1.32E-16
Kcnv2 potassium channel, subfamily V, member 2 -1.04 3.80E-06
Crip2 cysteine rich protein 2 -1.04 4.64E-04
A530058N18Rik RIKEN cDNA A530058N18 gene -1.03 1.59E-02
Ier2 immediate early response 2 -1.02 3.38E-02
Lbh limb-bud and heart -1.02 3.78E-20
Pkig protein kinase inhibitor, gamma -1.02 1.06E-13
Cnga3 cyclic nucleotide gated channel alpha 3 -1.02 3.06E-06
C130080G10Rik RIKEN cDNA C130080G10 gene -1.02 1.49E-14
Pdzrn3 PDZ domain containing RING finger 3 -1.01 4.22E-07
Stk39 serine/threonine kinase 39 -1.01 7.95E-15
Fig4 FIG4 homolog (S. cerevisiae) -1.01 2.15E-09
Gm17473 predicted gene, 17473 -0.99 2.12E-02
S1pr5 sphingosine-1-phosphate receptor 5 -0.99 4.28E-02
Lrrc3b leucine rich repeat containing 3B -0.98 3.77E-03
Ctgf connective tissue growth factor -0.98 4.19E-03
Lrrc10 leucine rich repeat containing 10 -0.96 1.02E-05
Ctnna1 catenin (cadherin associated protein), alpha 1 -0.96 4.30E-13
Ier5 immediate early response 5 -0.95 2.41E-02
Klhl34 kelch-like 34 -0.94 1.09E-04
Ano10 anoctamin 10 -0.94 2.74E-13
Ighg2c immunoglobulin heavy constant gamma 2C -0.94 1.78E-03
Aldh1l2 aldehyde dehydrogenase 1 family, member L2 -0.93 2.28E-08
Gm15770 predicted gene 15770 -0.93 4.18E-02
Cox17 cytochrome c oxidase assembly protein 17 -0.93 3.72E-08
Daam1 dishevelled associated activator of morphogene-
sis 1 
-0.90 4.03E-09
Lclat1 lysocardiolipin acyltransferase 1 -0.89 1.51E-03
Cmya5 cardiomyopathy associated 5 -0.89 2.13E-03
Mrpl12 mitochondrial ribosomal protein L12 -0.88 4.95E-02
Amph amphiphysin -0.88 3.44E-03
Gm17281 predicted gene, 17281 -0.87 7.57E-08
4430402I18Rik RIKEN cDNA 4430402I18 gene -0.86 1.98E-03
Spint2 serine protease inhibitor, Kunitz type 2 -0.85 3.00E-02
Adrbk2 adrenergic receptor kinase, beta 2 -0.85 3.80E-06
Clasp1 CLIP associating protein 1 -0.84 1.64E-04
Ankrd23 ankyrin repeat domain 23 -0.83 1.69E-02
Pgf placental growth factor -0.82 1.56E-03
Ehbp1 EH domain binding protein 1 -0.82 8.08E-16
Myl1 myosin, light polypeptide 1 -0.82 3.72E-02
Il15 interleukin 15 -0.82 2.72E-03
Abca12 ATP-binding cassette, sub-family A (ABC1), mem-
ber 12 
-0.81 3.60E-07
Grb14 growth factor receptor bound protein 14 -0.81 4.08E-20
Tmem56 transmembrane protein 56 -0.81 9.98E-03
Hfe2 hemochromatosis type 2 (juvenile) -0.81 2.86E-07
Adra1b adrenergic receptor, alpha 1b -0.80 4.95E-06
Cryab crystallin, alpha B -0.80 5.13E-03
Casq1 calsequestrin 1 -0.80 1.18E-02
Kcnip2 Kv channel-interacting protein 2 -0.80 2.46E-12
Hspb1 heat shock protein 1 -0.80 7.39E-03
116 117
Table 39. Downregulated genes with a log2-fold-change (L2FC) >0.8 and p <0.05
external_gene_id description L2FC padj 
Gm8420 predicted gene 8420 3.15 4.73E-20
Cd226 CD226 antigen 1.93 1.17E-07
AI593442 expressed sequence AI593442 1.75 5.63E-08
Ppbp pro-platelet basic protein 1.65 3.63E-05
D630024D03Rik RIKEN cDNA D630024D03 gene 1.58 5.45E-05
F5 coagulation factor V 1.56 3.62E-04
A930033H14Rik RIKEN cDNA A930033H14 gene 1.50 9.10E-07
Btla B and T lymphocyte associated 1.49 1.59E-04
Tubb1 tubulin, beta 1 class VI 1.41 1.55E-03
Gapdh glyceraldehyde-3-phosphate dehydrogenase 1.40 8.28E-06
Lypd6 LY6/PLAUR domain containing 6 1.28 1.51E-03
Raph1 Ras association (RalGDS/AF-6) and pleckstrin ho-
mology domains 1 
1.22 4.56E-04
Siglec1 sialic acid binding Ig-like lectin 1, sialoadhesin 1.21 3.52E-04
Gm15626 predicted gene 15626 1.19 1.93E-03
Itga2b integrin alpha 2b 1.18 1.38E-02
Casc5 cancer susceptibility candidate 5 1.16 9.43E-04
Wisp2 WNT1 inducible signaling pathway protein 2 1.16 2.41E-06
Scgb1c1 secretoglobin, family 1C, member 1 1.16 1.93E-05
Vaultrc5 vault RNA component 5 1.15 7.36E-03
Cubn cubilin (intrinsic factor-cobalamin receptor) 1.15 8.81E-04
Gm4951 predicted gene 4951 1.14 1.22E-03
Acox2 acyl-Coenzyme A oxidase 2, branched chain 1.14 4.62E-03
Gm10115 predicted gene 10115 1.13 1.25E-02
Ctla2a cytotoxic T lymphocyte-associated protein 2 alpha 1.13 5.02E-09
Rgs18 regulator of G-protein signaling 18 1.13 1.69E-03
Gm17388 predicted gene, 17388 1.12 1.46E-02
Clec1b C-type lectin domain family 1, member b 1.12 2.66E-02
Gp9 glycoprotein 9 (platelet) 1.11 2.78E-02
Mx2 myxovirus (influenza virus) resistance 2 1.11 2.56E-04
Snora23 small nucleolar RNA, H/ACA box 23 1.10 8.82E-03
Marveld2 MARVEL (membrane-associating) domain con-
taining 2 
1.09 4.12E-03
Psca prostate stem cell antigen 1.09 2.26E-02
B230325K18Rik RIKEN cDNA B230325K18 gene 1.07 1.73E-02
Gm12250 predicted gene 12250 1.06 2.90E-03
Gm25835 predicted gene, 25835 1.06 2.12E-04
Gm10615 predicted gene 10615 1.05 1.32E-02
Gm22710 predicted gene, 22710 1.04 2.69E-03
5430416N02Rik RIKEN cDNA 5430416N02 gene 1.04 1.80E-02
A430110L20Rik RIKEN cDNA A430110L20 gene 1.04 3.01E-02
Slfn8 schlafen 8 1.03 3.97E-02
Snord15a small nucleolar RNA, C/D box 15A 1.02 9.62E-05
Gm15675 predicted gene 15675 1.02 2.30E-02
P2ry12 purinergic receptor P2Y, G-protein coupled 12 1.02 1.51E-03
Ddx60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 1.02 1.72E-10
Angptl7 angiopoietin-like 7 1.02 6.64E-04
Trim59 tripartite motif-containing 59 1.00 1.99E-02
Trpc6 transient receptor potential cation channel, sub-
family C, member 6 
1.00 2.28E-02
Slc6a4 solute carrier family 6 (neurotransmitter trans-
porter, serotonin), member 4 
1.00 2.85E-02
Ckap2 cytoskeleton associated protein 2 1.00 3.60E-02
Gm16586 predicted gene 16586 1.00 9.42E-05
Rorb RAR-related orphan receptor beta 0.98 1.36E-02
Trim67 tripartite motif-containing 67 0.98 2.65E-03
Mir1949 microRNA 1949 0.98 9.50E-03
Gm16340 predicted gene 16340 0.98 1.34E-02
Ccl8 chemokine (C-C motif) ligand 8 0.98 2.54E-02
Npas2 neuronal PAS domain protein 2 0.98 4.74E-02
Ikzf1 IKAROS family zinc finger 1 0.97 4.40E-03
A930039A15Rik RIKEN cDNA A930039A15 gene 0.97 1.74E-02
S100a4 S100 calcium binding protein A4 0.96 4.96E-03
Gm25791 predicted gene, 25791 0.94 6.00E-05
Gm26165 predicted gene, 26165 0.93 1.21E-02
Ifi204 interferon activated gene 204 0.92 1.02E-02
Ifit1 interferon-induced protein with tetratricopeptide 
repeats 1 
0.92 8.19E-05
H2-Q6 histocompatibility 2, Q region locus 6 0.92 2.82E-03
Tfcp2l1 transcription factor CP2-like 1 0.92 1.03E-02
Creb5 cAMP responsive element binding protein 5 0.92 8.35E-03
F630028O10Rik RIKEN cDNA F630028O10 gene 0.91 1.24E-04
118 119
Prg4 proteoglycan 4 (megakaryocyte stimulating fac-
tor, articular superficial zone protein) 
0.91 1.51E-04
2610203C20Rik RIKEN cDNA 2610203C20 gene 0.91 1.74E-02
Zfhx4 zinc finger homeodomain 4 0.91 2.66E-02
Adam33 a disintegrin and metallopeptidase domain 33 0.90 3.69E-02
Gm23442 predicted gene, 23442 0.90 6.35E-04
Papd4 PAP associated domain containing 4 0.90 9.12E-03
Gm26397 predicted gene, 26397 0.89 7.54E-04
Cd84 CD84 antigen 0.89 4.60E-04
Gm21781 predicted gene, 21781 0.89 1.89E-02
Plek pleckstrin 0.88 1.62E-02
Arhgap15 Rho GTPase activating protein 15 0.88 2.41E-02
Rbm3 RNA binding motif protein 3 0.87 6.07E-06
Clec10a C-type lectin domain family 10, member A 0.87 1.75E-03
Myo1g myosin IG 0.86 3.82E-02
Sntb1 syntrophin, basic 1 0.86 1.53E-03
Zfp960 zinc finger protein 960 0.85 5.60E-03
Irf7 interferon regulatory factor 7 0.84 8.99E-05
Mamld1 mastermind-like domain containing 1 0.84 4.80E-02
Clec5a C-type lectin domain family 5, member a 0.84 3.46E-02
Fermt3 fermitin family homolog 3 (Drosophila) 0.84 3.88E-03
4931406C07Rik RIKEN cDNA 4931406C07 gene 0.83 8.67E-05
Dlg2 discs, large homolog 2 (Drosophila) 0.83 2.06E-02
Hpse heparanase 0.83 3.84E-02
Gm12940 predicted gene 12940 0.81 2.69E-02
Ifit2 interferon-induced protein with tetratricopeptide 
repeats 2 
0.80 1.09E-04
4930529M08Rik RIKEN cDNA 4930529M08 gene 0.80 1.66E-02
